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Abstract 
Background: Canine primary immune mediated hemolytic anemia (pIMHA) is the most common immune-
hematological disease in dogs. It involves the destruction of red blood cells by the immune system resulting in 
moderate to severe anemia in most patients. Despite its frequent description in the literature, only a few authors 
have described the vast range of morphological abnormalities of erythrocytes, leukocytes and platelets that may 
be present in the presentation of the disease.  
Objectives: To investigate retrospectively clinical and clinicopathological findings in two groups of dogs with 
pIMHA, as well as to describe the alterations most commonly observed in patients' peripheral blood smears. 
Cases were collected at the "Mario Modenato" Veterinary Teaching Hospital of the Department of Veterinary 
Sciences, Pisa University, Italy (Pisa) and the Veterinary Teaching Hospital of the Koret School of Veterinary 
Medicine, Hebrew University of Jerusalem, Israel (Beit-Dagan).  
Material and Methods: Fifty-two cases of canine pIMHA between the years 2009 and 2015 were collected. 
Signalment, clinical findings, and clinicopathological results (complete blood count and biochemical profile) 
between the two groups and with a control group (only for Pisa cases) were compared statistically. 
Results: The entire study group was composed mainly of middle-aged and elderly dogs. Neutered females were 
overrepresented, as well as the Cocker-Spaniel and the Maltese breeds. No seasonal predisposition was found. 
The comparison between the two groups (Pisa and Beit Dagan) shows: tachycardia, tachypnea and icterus were 
significantly more frequent in the Israeli group (P=0.017, 0.001 and 0.048 respectively); MCV, MCHC and 
RDW varied significantly (P= 0.004, 0.001 and 0.018 respectively) and so did the absolute lymphocyte count 
(P=0.001) and the total protein measurement (P=0.02).  
Conclusions: This study of canine pIMHA from two different sites confirms the findings previously described in 
the literature in regards to the clinical and clinicopathological alterations occurring in this disorder even if 
different diagnostic approaches were noticed. The Beit-Dagan group was characterized by a more severe and 
acute onset of IMHA, with more evidence of intravascular hemolysis and a slightly lower Hct median. A 
significant correlation between NRBCs, band neutrophils and macrothrombocytes was evidenced that could be 
related to extra-medullary hemopoiesis. The occurrence of schistocytes and macrothrombocytes could help 
diagnosing a coagulation disorder. The review of the blood smear is valuable in diagnosing and monitoring of 
the disease. 
Keywords: Immune mediated hemolytic anemia; Dog; Retrospective study; Clinical findings; 
Clinicopathological results; two veterinary teaching hospitals. 
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Riassunto 
Anemia Emolitica Immuno-mediata Primaria nel Cane: Studio Retrospettivo di 52 Casi Osservati Presso 
Due Ospedali Didattici Veterinari (2009-2015) 
 Background. L'anemia emolitica immunomediata primaria (pIMHA) è la malattia immunoematologica più 
comune nei cani. Comporta la distruzione dei globuli rossi da parte del sistema immunitario con conseguente 
anemia da moderata a grave in molti pazienti. Nonostante sia stata frequentamente descrita in letteratura, solo 
pochi autori hanno sottolineato la vasta gamma di anomalie morfologiche degli eritrociti, leucociti e piastrine 
che possono essere presenti nel corso della malattia.  
Animali. Questo studio retrospettivo ha indagato le alterazioni cliniche e clinico-patologiche presenti in 
cinquantadue casi di anemia emolitica immunomediata canina visitati  tra gli anni 2009 e 2015. I casi sono stati 
raccolti in due ospedali didattici veterinari: l'Ospedale Didattico Veterinario “Mario Modenato” del Dipartimento 
di Scienze Veterinarie, Università di Pisa, Italia  e l'Ospedale Didattico Veterinario al " Koret School of 
Veterinary Medicine", Università Ebraica di Gerusalemme, Israele. 
Obiettivi. indagare i risultati clinici e clinico-patologici in due gruppi di cani con pIMHA, nonché per descrivere 
le alterazioni più comunemente osservate nello striscio di sangue periferico dei pazienti. 
Risultati. Il nostro gruppo di studio è composto principalmente da cani di mezza età. Le femmine sterilizzate 
sono sovrarappresentate, così come la razza Cocker-Spaniel e la razza Maltese. Inoltre si è dimostrato che non 
esiste una predisposizione stagionale alla patologia. Tachicardia , tachipnea e ittero sono stati osservati in modo 
significativamente più frequente nel gruppo israeliano rispetto a quello italiano (P=0.017, 0.001 e 0.048 
rispettivamente). Inoltre alcuni indici eritrocitari (MCV,MCHC e RDW) risultavano significativamente diversi 
tra il gruppo israeliano e quello italiano(P=0.004, 0.001 e 0.018 rispettivamente), cosi come la conta linfocitaria 
(P=0.001) e la misurazione delle proteine totali (P=0.02).  
Conclusioni. Lo studio conferma i risultati descritti precedentamente in letteratura per quanto concerne il 
segnalamento e le alterazioni cliniche e clinico-patologiche di pIMHA anche se differenti approcci diagnostici 
sono stati osservati. Il gruppo di Beit Degan è caratterizzato da una osservazione in fase più acuta, con maggiore 
evidenza di casi di emolisi intravascolare e Hct medio più ridotto. Una correlazione significativa tra NRBC, 
neutrofili banda e macrotrombocitosi è stata osservata e potrebbe essere correlata ad una ematopoiesi 
extramidollare. La presenza di schistociti con macrotrombocitosi potrebbe facilitare la diagosi di disordini 
coagulativi. La valutazione dello striscio ematico è utile nella diagnosi e monitoraggio della patologia.  
Parole chiave:anemia emolitica immunomediata; cane; casi retrospettivi; riscontri clinici; riscontri 
clinico-patologici; due ospedali didattici veterinari. 
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Introduction 
The term anemia indicates a pathologic condition characterized by a decreased concentration of 
hemoglobin (Hb) in blood and/or a decreased number of erythrocytes (RBC) and/or decreased 
hematocrit (Ht). Anemia can arise in one of two mechanisms; decreased RBC production, which leads 
to non regenerative anemia or decreased life-span of erythrocytes. The latter provokes a regenerative 
response with release of reticulocytes from bone marrow in attempt to restore the RBC mass. Reduced 
RBC life-span due to hemolysis is a common occurrence in small animal veterinary clinical practice. 
Hemolysis can originate from various etiologies including infective (e.g. Clostridium spp., Leptospira 
spp., Babesia spp.), toxic (e.g. consumption of onions leading to Heinz Body anemia, zinc intoxication 
and snake venom), mechanical damage (e.g. microangiopatic hemolytic anemia, vena-caval syndrome) 
and metabolic disorders (e.g. hypophosphatemia, pyruvate kinase deficiency), to name a few
1
. 
Nevertheless, the most common hemolytic anemia in dogs is the immune mediated hemolytic anemia 
(IMHA). In most cases canine IMHA is considered to be auto-immune 
2
 (idiopathic or primary).  
Auto-immune diseases represent some of the most frustrating types of disorders that are diagnosed and 
treated in veterinary medicine. Given the nature of these diseases, in which an abnormal immune 
response against the body's own cells arise, treatment is difficult and necessarily includes suppression 
of immune defenses
3
.     
 Primary IMHA (pIMHA) is a severe disease with high mortality rates, mainly in the first two weeks 
that follow its presentation
4
. Due to its complex pathophysiology and the numerous components that 
take part in the pathological mechanisms that cause it, pIMHA has been the subject of numerous 
studies, in veterinary and human medicine alike.  
The first part of this work is aimed to thoroughly review the pathological mechanisms, diagnostic 
approaches, treatment options and outcome prediction scales described by the scientific veterinary 
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literature. Some references from human hematology literature were used. These references were used 
for means of comparison to veterinary medicine with the intra-species variation in mind. 
The second part of this work includes a retrospective study of fifty-two cases of canine primary 
immune mediated hemolytic anemia. Cases were collected from two veterinary teaching hospitals in 
two different countries; Italy and Israel. The goals of this study were to analyze the various clinical 
signs, symptoms and clinicopathological alterations of this complex disease and to compare them 
between the two hospitals and the corresponding findings described in veterinary scientific literature. 
   
    
 
Chapter two: Definition and Patient Profiling 
2.1 Definition 
Immune-mediated hemolytic anemia (IMHA) is the most common severe anemia of dogs and 
is less frequent in cats
5
. The majority of cases (at least in North America, Northern Europe 
and Australia) are currently considered to be primary IMHA
6
.  It is also reported to be the 
most common immune-mediated disease of dogs 
4
.  
IMHA involves the destruction of red blood cells via type II hypersensitivity (antibody- 
dependent cytotoxicity), and may arise the following: 
1. binding of autoantibody to a structural component of the erythrocyte membrane in the 
absence of an underlying disease (Primary idiopathic IMHA)
7
. This type of anemia is also 
known as Auto Immune Hemolytic Anemia (AIHA) – a term currently used almost 
exclusively in human medicine since that in dogs, it is virtually impossible to exclude with 
certainty the presence of a precipitating factor that could have triggered or caused the disease. 
In Humans, a much lower percentage of cases of AIHA are idiopathic (25 to 30% compared 
with 60 to 75% in dogs)
8
. This reinforces the importance of thoroughly investigating canine 
cases for an underlying cause which may be of therapeutic and prognostic value
9
.   
2. Binding of cross-reactive antibody, i.e., antibody with specificity for a drug or infectious 
agent, or for membrane antigens exposed or modified by such agents (secondary IMHA) 
7
. 
. 
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2.2 Classification of IMHA 
Immune anemias are classified on the basis of mechanism or association. Serologically there 
are two types: warm-antibody type with maximal activity at 37°C and cold-antibody type with 
maximal activity at 2-4°C.  
Classification by association is based on the identification of an underlying cause and 
includes primary, idiopathic immune hemolytic anemia (pIMHA) and secondary  immune 
hemolytic anemia
10
.  
Secondary IMHA occurs when there is an underlying reason for the attachment of 
immunoglobulin to RBCs. For example, IMHA may occur as a secondary phenomenon in 
neoplastic disease or when the antibody has affinity for an infectious agent or drug that is 
associated with the RBC surface. In these latter cases, the RBC destruction is due to -  
“bystander hemolysis ” as the causative antibody is not specific for the RBC itself 6. 
In dogs, there are many conditions that can cause secondary IMHA; blood parasites such as 
Ehrlichia spp and Babesia spp, lymphoid malignancies 
11
(such as lymphoma and 
myeloproliferative disease), erythroid malignancies (such as heamangiosarcoma 
6
) and poorly 
differentiated malignancies 
12
. Some drugs such as Cephalosporins 
13
, Carprofen 
14
 and others, 
may also be considered as a cause for secondary IMHA. 
The most controversial association is the one proposed between the development of canine 
IMHA and vaccination in the immediately preceding 4 - week period. Anecdotal evidence for 
this association has been available for some time;  
A pivotal study by Duval and Giger provided evidence for a temporal relationship of vaccine - 
associated IMHA in the dog
15
. However, a large epidemiologic survey that was subsequently 
conducted in the United Kingdom failed to support these findings. In this study, there was no 
clear evidence that dogs with Coombs’ - positive IMHA were more likely to have been 
recently vaccinated. Overall, it appears that vaccine - associated IMHA does occur in dogs but 
with low incidence. The report of the United Kingdom Veterinary Products Committee 
provided specific data from a pharmaco-vigilance data base which suggested that vaccine - 
associated with IMHA was a relatively rare occurrence (incidence of 0.001 per 10,000 doses 
of vaccine sold). The immunological mechanisms by which these reactions develop are not 
understood and no particular vaccine has been implicated 
6
. 
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By contrast, in primary idiopathic IMHA there is no underlying disease or evidence of recent 
drug or vaccine administration, and the antibody is considered to be a true autoantibody with 
affinity for a self - antigen of the RBC membrane. Only this form of disease is true 
autoimmune hemolytic anemia (AIHA). This may occur as a single clinical entity, or may be 
recognized concurrently with primary immune - mediated thrombocytopenia (IMT; the 
combined disease is Evans’ syndrome), primary immune - mediated neutropenia (IMN) or be 
part of the multi systemic autoimmune disease, i.e. systemic lupus erythematosus (SLE)
6,11
. 
Activation of auto-reactive lymphocytes is generally considered to reflect a failure of natural 
regulation (suppression) of such cells 
6
. 
The onset of the disease might also be the result of a well documented immunological 
mechanism known as molecular mimicry. Molecular mimicry has been proposed as a 
pathogenic mechanism for autoimmune disease in humans as well as in animals. It is defined 
as similar structures shared by molecules from dissimilar genes or by their protein products. 
Either the molecules’ linear amino acid sequences or their conformational fits may be shared, 
for example, by a virus and a normal host–self determinant. An immune response against the 
determinant shared by the host and the virus can evoke a tissue-specific immune response that 
is presumably capable of eliciting cell and tissue destruction. The probable mechanism is 
generation of cytotoxic cross-reactive effector lymphocytes or antibodies that recognize 
specific determinants on target cells 
16
. In the latter case the anemia would still be considered 
primary.  
 
 
 
2.3 Factors Predisposing to Canine Primary IMHA  
A number of factors predisposing to the development of primary IMHA are defined in the 
dog. Domestic dogs have been actively line-bred for the past few hundred years to achieve 
extreme phenotypic variation between different pedigrees, but minimal genetic variation still 
remains between breeds. Such breeding programs have inadvertently resulted in differences in 
breed susceptibility to certain immune-mediated diseases, including IMHA, diabetes, 
hypothyroidism and Addison's disease. With the completion of the Dog Genome Assembly 
and initiation of ongoing breed genetic diversity projects, comparative genomic studies in 
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diseases, including IMHA, could provide important information into such complex genetic 
disorders. 
There is a strong genetic influence suggested by the greater prevalence of the disease in 
particular breeds (e.g. Old English Sheep dog, Cocker Spaniel, Border Collie, Poodle, English 
Springer Spaniel, Irish Setter, Miniature Schnauzer) and within particular pedigrees. Studies 
have revealed associations with allotypes and haplotypes of genes of the major 
histocompatibility complex (MHC), which are strongest when specific breed groups are 
considered
6,17
. In one study the overall patient group was divided on the basis of individual 
breeds with more than six animals represented and each of the haplotypes could be shown to 
be implicated in one of the breeds. Thus, it is apparent that different breeds had different 
MHC associations with canine IMHA
18
.  Some MHC haplotypes increase susceptibility to 
IMHA, whereas others appear to confer protection 
18
. One report has suggested that 
expression of the blood group antigen DEA 7 in Cocker Spaniel dogs reduces susceptibility to 
IMHA 
19
. 
2.4 Signalment and Clinical Presentation  
Canine primary IMHA is generally a disease of middle-aged (6 – 8 years) dogs 6,7,17. 
Although there is no clear gender predisposition, there is a slight overrepresentation of female 
neutered dogs
11,17
. The disease can also be precipitated in bitches by the stress of whelping or 
estrus
6,7
. Some studies suggest that intact male dogs might be less prone to the disease. The 
latter may indicate that androgens are protective in the face of the disease 
20
.   
There are two main clinical presentations of canine IMHA: 
Acute onset (1-2 days) 
May be presented with severe intravascular hemolysis with jaundice, hemoglobinemia and 
hemoglobinuria (red or dark brown urine), As well as pyrexia and vomiting 
6,7
. This form of 
the disease is less common. 
Chronic onset (days or weeks) 
May be presented with weakness, lethargy, exercise intolerance, anorexia, pyrexia, pallor of 
mucous membranes, tachypnoea, tachycardia, hepatosplenomegaly, lymphadenomegaly 
6,7
. 
This is the more common form of the disease. 
11 
 
Hematological examination may reveal: Moderate to severe anemia (5-20 PCV); Marked 
reticulocytosis and polychromasia (3- 4+); gross or microscopic auto agglutination of blood 
and a moderate to severe spherocytosis 
5
. Marked leukocytosis is typically present and is 
characterized by a strong neutrophilia 
7
, possibly in combination with monocytosis. The 
presence of band neutrophils has also been reported 
8
. 
The definitive diagnostic test is the demonstration of erythrocyte-bound antibody and/or 
complement by flow-cytometry or Coombs' test 
7
. A proportion of dogs with IMHA will 
subsequently develop disseminated intravascular coagulation and/or pulmonary 
thromboemboli. 
 
Chapter three: Immunopathogenesis of Primary IMHA 
 
3.1 Pathophysiology of Hemolysis 
Anemia of hemolysis develops when the rate of destruction exceeds that of production. Since 
the products of hemoglobin catabolism are readily reutilized, the anemia of hemolysis is 
characteristically and predominantly highly responsive with reticulocytosis and an upward 
shift in mean corpuscular volume (MCV). It is stated that human marrow can increase output 
6-fold in hemolytic anemia and cats and dogs have a similar capacity for regeneration.  
Intracellular destruction of red cells is the normal route of removal and occurs in the 
monocyte-macrophage system in the bone marrow, spleen, liver and lymph nodes. In 
hemolytic states, the spleen may become quantitatively more important than marrow. The 
actual process of lysis is rapid and if erythrophagocytosis is observed, the level of destruction 
is likely also rapid. This catabolism releases iron from heme to transferrin or to storage as 
ferritin or hemosiderin, while the protoporphyrin ring is opened and released to the plasma as 
unconjugated bilirubin. Intravascular destruction of red cells occurs in normal circumstances 
at a very low rate as a result of high velocity trauma in small arteries. In some cases of 
accelerated hemolysis with complement fixation, red cells are lost by intravascular lysis at 
very rapid rates resulting in hemoglobinuria.  
Adherence of antibody to the red cell membrane, with or without complement fixation, can 
cause red cells to undergo partial erythrophagocytosis which gives them the spherical shape. 
11 
 
Their lifespan is then reduced either by destruction by the monocyte - macrophage system or 
by intravascular hemolysis. Since the damage is usually to the most mature cells, most 
hemolytic anemias are highly responsive 
6,10
. 
 
3.2 Auto - antibody Etiology 
The etiology of most RBC auto-antibodies is not well understood. Given the association 
between IMHA and other autoimmune disorders, generalized immune system dysfunction 
likely plays a role. The relationship between pIMHA and lymphoproliferative disorders and 
other neoplasms likewise suggest generalized dysfunction of immune surveillance. The 
immune system has meny control points that keep a balance between the need to tolerate self-
antigens and the need to appropriately respond to foreign antigens. Distruption of any of those 
processes may be a potential cause of auto-immune disease. 
The variety of mechanisms that are involved in the control of self - reactive lymphocytes 
include: 
 (1) central deletion of T cells with such specificity, as part of intrathymic development and of 
auto- reactive B cells during development in the bone marrow;  
(2) peripheral deletion of self - reactive T cells upon exposure to autoantigenic peptide outside 
of the thymus;  
(3) the induction of anergy by exposure to autoantigen in the absence of delivery of 
costimulatory signals;  
(4) immunological ignorance due to failure to present autoantigen to the autoreactive 
populations, and  
(5) active suppression by regulatory lymphocytes.  
Particular advances have been made recently with respect to understanding of the last 
component. A population of  “natural suppressor” T cells defined by expression of CD4 and 
CD25 is thought to be constitutively present within the immune system in order to prevent the 
activation of pathogenic T cells specific for autoantigen or allergen. These “Treg” cells are 
further defined by expression of specific genes (e.g. Foxp3, GITR). Although Treg cells 
secrete the immunoregulatory cytokine IL – 10, they are thought to require direct contact 
12 
 
(“cognate interaction”) with the target cells they intend to regulate. Treg cells have now been 
identified in the dog 
21
 and it is likely that suboptimal function of this population occurs in 
canine autoimmunity. Other T cell types are also known to have suppressive function. 
Overall, T regulatory cells are involved in dampening an immune response after they have 
successfully tackled invading organisms as well as keeping in check immune responses that 
may potentially attack one’s own tissues 6. 
Another central player in maintaining peripheral tolerance is the dendritic cell (DC). The DC 
is a antigen-presenting cell that processes and presents antigen in the context of MHC I and II 
to naïve T cells. CD4
+ 
 T cells that engage the MHC II/Ag complex may differentiate into T-
Helper (Th) subtype in the presence of a co-stimulatory signal produced by the DC. Dendritic 
cells do not express the requisite co-stimulatory signal unless they have been activated by 
certain triggers, such as signaling through pattern recognition receptors (PRRs) by pathogen-
associated molecular patterns (PAMPs) and some cytokines including TNFα. In the absence 
of a co-stimulatory signal the T cell is rendered anergic or undergoes apoptosis. DCs also 
appear to direct the differentiation and proliferation of a subset of T regulatory cells known as 
inducible T regs. Signals produced during interaction of T cells with DC may induce 
differentiation into various T cell subtypes  that mediate different responses in the immune 
system. Since activation of particular subsets is associated with immune-mediated diseases, 
the ability of DC to facilitate differentiation of certain T cell subtypes may be important for 
understanding the mechanisms involved in auto-immunity 
9
. 
 
Less generalized autoimmune processes also exist. For example auto immune disease can 
arise from the response to a foreign antigen, if it shows sufficient homology with a self-
antigen ("molecular mimicry"). Another theoretical source of auto-antibodies is a malignant B 
cell clone, but RBC auto-antibodies are generally polyclonal. On the basis of studies made 
with other human auto-immune disorders, such as ankylosing spondilitis and multiple 
sclerosis, as well as in veterinary auto-immune disorders, both genetic and environmental 
factors likely play a role in the production of RBC auto-antibodies 
6,22
.  
In the course of Primary IMHA, both IgM and IgG autoantibodies are found, and particular 
subclasses (IgG1 and IgG4) dominate the IgG response 
23
. Significant quantities of IgA may 
also be associated with the erythrocyte membrane in AIHA, but the presence of this 
immunoglobulin is of questionable relevance. The specificity of the IgG autoantibodies has 
13 
 
been characterized by eluting them from the surface of patient RBCs and incubating them 
with biotin - labeled normal canine RBC in the technique of immunoprecipitation. These 
autoantibodies are directed against various components including erythrocyte membrane 
glycophorins, the anion exchange molecule (band 3) and the cytoskeletal molecule 
spectrin
24,25
. Recent studies have identified reactivity to calpain, complement component 3, 
and peroxiredoxin 2 in some dogs with AIHA, but not in healthy dogs. These proteins are 
involved in oxidative stress and apoptosis (calpain), inflammation (complement), and 
scavenging of reactive oxygen species (peroxiredoxin 2). It remains to be determined if these 
proteins are important in initiating autoimmunity or if immunoglobulins targeting these 
proteins develop during IMHA
26
.  
 
3.3 Immunopathogenesis of pIMHA  
Factors underlying the development of a true autoimmune response are complex, and even 
now, not entirely understood. As mentioned previously, the expression of any autoimmune 
disease requires that a combination of predisposing factors permit the development of an 
immunological alteration resulting in the observed autoimmune pathology. Such 
immunological alterations have been experimentally investigated using murine models of 
pIMHA. For example, pIMHA may be induced in particular inbred strains of mice that are 
immunized with rat RBCs, or that are transgenic for high expression of interleukin (IL) - 4, or 
expression of an RBC autoantibody. IL - 2 deficient mice, created by targeted disruption of 
the IL - 2 gene, develop a lymphoproliferative syndrome with multisystemic autoimmunity, 
including Coombs’ positive hemolytic anemia. New Zealand black (NZB) mice 
spontaneously develop autoimmunity including IMHA or a SLE - like disease, characterized 
by immune complex glomerulonephritis and serum antinuclear antibody (ANA). The IMHA 
is mediated by CD4 + Th1 lymphocytes that are first activated in very young mice before the 
appearance of auto-antibodies and anemia. A strain of non - obese diabetic (NOD) mice that 
develop autoimmune destruction of pancreatic beta cells mediated by T cells, culminating in 
insulin - dependent diabetes mellitus, may also develop Coombs’ - positive hemolytic anemia 
late in life. However, the immune mediated anemia in the NOD strain may occur in both 
diabetic and non - diabetic mice 
6
. 
It is now also believed that microbial infection is of particular importance in the induction of 
autoimmune diseases. Clinically normal individuals have circulating lymphocytes that are 
14 
 
programmed to recognize self - antigens, but these cells are normally incapable of responding 
to autoantigens (self - tolerance). The altered immune regulation that follows infection may 
permit loss of self - tolerance and the subsequent expression of autoimmune disease. For 
example, mice infected with a particular substrain of the lymphocytic choriomeningitis virus 
develop transient IMHA. In this instance the anemia is not caused by antibodies that react 
with a shared epitope on the virus and RBC, but by true erythrocyte specific autoantibodies 
27
. 
The induction of this autoimmune response is thought to be due to inappropriate activation of 
autoreactive T cells by virally - derived peptides that are “ molecular mimics ” of erythrocyte 
- derived peptides; these peptides would normally not be presented by the antigen presenting 
cells (APCs) of the immune system and thus, autoreactive T cells are maintained in a state of 
“ immunological ignorance ”. It is also possible that the presence of infectious agents or their 
molecular components (LPS from bacteria, RNA from virus etc.) facilitate T-cell activation 
by acting as costimulatory molecules during APC antigen presentation
9
.  
A series of investigations has revealed many parallels between canine pIMHA and the disease 
in humans and experimental rodent models. The autoantibodies that characterize the canine 
disease are heterogeneous in their class and specificity, suggesting that a range of different 
underlying mechanisms may be involved in triggering the disease. Both IgM and IgG 
autoantibodies are found, and particular subclasses (IgG1 and IgG4) dominate the IgG 
response 
25
. Significant quantities of IgA may also be associated with the erythrocyte 
membrane in pIMHA, but the presence of this immunoglobulin is of questionable relevance.  
T cell reactivity in canine pIMHA has also been examined. Like other species, clinically 
normal dogs harbour RBC - reactive lymphocytes that can be induced to proliferate in vitro 
when challenged with RBC - derived antigens. Such cells have a greater degree of reactivity 
when they are obtained from dogs recovered from pIMHA (memory lymphocytes) or from 
normal dogs that are closely related to pIMHA cases
28
. The latter observation suggests an 
immunological mechanism for genetic susceptibility to pIMHA in dogs. It is important to 
further investigate the fine specificity of such autoimmune responses, as this knowledge will 
form the basis for developing novel immuno therapeutic agents in future years. 
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3.4 Mechanisms of immune destruction of red blood cells 
In patients with pIMHA there is strong evidence that the coating of auto antibodies per se, 
does not damage the red cells but causes erythrocyte destruction by complement activation 
and/or by inducing interactions with cells of the mononuclear phagocyte system 
(opsonization). Erythrocyte destruction may be extra- or intravascular. In most patients, 
hemolysis is extravascular and involves mononuclear phagocytes reacting with erythrocytes 
coated with antibodies of lgG, IgM class and with C3b. IgA may also be associated with the 
erythrocyte membrane, but as mentioned before this antibodies don't seem to be involved in 
the pathological process 
6
. Destruction of IgG coated cells usually occurs in the spleen, but 
when the coating is heavy it may occur anywhere in the mononuclear phagocyte system. Less 
frequently, destruction occurs intravascularly, either through the activation of complement, or 
more controversially, through the erythrocytes interacting with lymphoid and granulocytic 
cells 
29
. 
3.4.4  Intravascular Destruction by Complement 
Intravascular hemolysis is seen in less than 20% of patients with pIMHA; it occurs if 
complement activation proceeds to completion, when the resultant defect in the erythrocyte 
membrane causes osmotic lysis of the cell. Deposition of the terminal C5b-9 complex on 
erythrocytes of patients with AIHA has been demonstrated using a radioisotopic method. 
Antibodies which trigger this process are called hemolysins; most are of IgM class though 
some are lgG. Complement-induced lysis is the most efficient method of red cell destruction 
and causes severe anemia; fortunately it is uncommon since the in vivo activity of hemolysins 
is restricted by their optimal temperature of activity being well below 37ºC. Hemolysis is 
never complete since regulatory inactivators operate at several levels of the complement 
cascade. In patients with pIMHA, inhibition occurs at the level of C3, however decrease in 
complement regulatory proteins that protect host cells from complement-mediated destruction 
has been shown in people with IMHA
9
. Erythrocytes coated with C3b can then be destroyed 
extravascularly by cells of the mononuclear phagocyte system 
29
. 
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3.4.5 Erythrocyte Mononuclear Phagocyte Interactions  
Erythrocyte-mononuclear phagocyte interactions in patients with AIHA are of particular 
interest. Their efficiency depends on several factors including the immunoglobulin class and 
subclass of the autoantibody, the number of antibody molecules bound per erythrocyte, the 
thermal range of the antibody, the ability of the antibody to activate complement, the amount 
of free IgG present in the surrounding medium and probably on the activity of the individual's 
macrophages. In most patients, the erythrocytes are coated with non - complement fixing IgG 
auto antibodies which induce red cell destruction by the attachment of the Fc portion of the 
IgG molecule to the macrophage surface at specific receptor sites. This adherence leads to 
erythrocyte membrane damage by ADCC (antibody dependent cell-mediated cytotoxicity) 
and to erythrophagocytosis. Whether ADCC or phagocytosis is the prime mechanism of 
erythrocyte destruction remains to be determined, though both may cause significant 
hemolysis in vivo. The amount of antibody bound to the cell seems to be important: using 
human blood monocytes and erythrocytes coated with human anti-Rhesus (Rh) D, it has been 
shown that the amount of phagocytosis is inversely proportional to the degree of sensitization. 
At low levels of sensitization, phagocytosis becomes more important than ADCC; the level at 
which this occurs is much lower with lgG4 than with lgG1 antibodies. Adherence to 
macrophages may also result in partial engulfment of the erythrocyte, leaving a non-
phagocytosed portion to become a rigid spherocyte, which is prematurely destroyed in the 
spleen. In vivo, splenic macrophages and Kupffer cells are the main effectors of red cell 
destruction, the blood monocytes appearing to play only a minor role. While IgG-coated cells 
are usually destroyed in the spleen, in situations where erythrocytes become coated with C3b 
alone, destruction (by phagocytosis and through the production of spherocytes) occurs mostly 
in the liver 
6,29
. 
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Chapter four: Clinical Aspects of Primary IMHA  
 
4.1 History and Common Owner Complaints 
Primary IMHA can be presented either as an acute hemolytic crisis or, more commonly, as a 
chronic mild onset, with a protracted (days to weeks) history of symptoms 
6,7
. Most authors 
describe the three most common symptoms as: weakness, anorexia and lethargy 
2,6,11,20
. These 
appear in 80-95% of the cases but have very little diagnostic value being highly non-specific. 
Other symptoms frequently observed by owners are: pigmenturia – red to dark brown colored 
urine in 44% of cases, vomiting  (30%), diarrhea (15%), hemorragic diathesis (15%) and 
syncopes (3%), based on Piek et al. extensive 2008 study 
2
. A thorough and accurate history 
and anamnesis is recommended in order to identify as much as possible a generating cause for 
the hemolysis such as tick borne disease or toxin exposure 
9
. 
 
4.2 Seasonal Incidence of Primary IMHA 
Studies have reported conflicting results regarding the seasonal incidence of IMHA, with 
some reporting a higher incidence in warmer months
11,15,30
 and others showing no 
association
20
. Suggested reasons for the apparent association include the effect of 
environmental temperature on immune responses, greater risk of dehydration or respiratory 
distress in warmer months, and the potential effect of an undetected infectious agent, such as 
Ehrlichia or Babesia, which occur more frequently during warm season
4
.    
 
4.3 Physical Examination Findings 
Physical examination discloses pale mucosae membrane in 98% of the patients. Pettechiae 
may be occasionally present as well, on the mucosae or epithelial membranes. This findings 
may indicate an additional, coexistent condition of thrombocytopenia (Evans' Syndrome). 
Other regularly observed clinical signs in IMHA patients are: increased body temperature, 
icterus and abdominal cranial organomegaly in seen in 46, 38 and 34 percent of patients 
respectively 
2
. Moreover, some dogs are presented with tachypnoea, tachycardia and 
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generalized lymphadenopathy. The latter being more common in the typical chronic onset of 
the disease 
6,7,11,20
. Some dogs with primary IMHA develop disseminated intravascular 
coagulation (DIC) or pulmonary thromboembolism, the effects and clinical signs of these 
conditions will be discussed in chapter 5. 
 
 
4.4 Heamatological and Clinicaopathological Alterations 
The hematological profile for primary IMHA is characterized by a moderate to severe 
macrocytic, hypochromic anemia, accompanied by a presence of spherocytes and/or auto 
agglutination. The hematocrit (Hct) percentage may range between 4-35% 
2
, with a most 
frequently reported median Hct of 15-13% 
2,20,31
. The authors have also reported that 80-90% 
of the dogs had an Hct percentage of less than 20. Mild to marked erythroid regeneration at 
initial presentation has been demonstrated in two thirds of the patients 
2,11,20,31
. As stated 
before the most common poikilocytosis in pIMHA dogs is spherocytosis, which is reported in 
70-90% of cases. The unique form of the spherocyte is due to partial loss of cell membrane in 
the process of extravascular erythrophagocytosis. Spherocytosis can also be diagnosed using 
the osmotic fragility test. The increased osmotic fragility reflects the fact that the surface 
membrane of the erythrocyte is reduced in size relatively to its volume, with the result that its 
capacity to swell before reaching the rupture point is reduced 
32
. Furthermore, reticulocytosis, 
polychromasia, anisocytosis, and nucleated RBCs are consistent features of pIMHA in the 
morphologic erythrocyte alterations 
6
. 
Auto agglutination in pIMHA patients is described by many authors 
2,7,15,33
. In one 
retrospective study 78% of pIMHA had evident auto agglutination on blood smear 
20
. True 
auto agglutination may be grossly distinguished from rouleaux formation by adding an equal 
volume of saline to blood (two drops each). Rouleaux will be dispersed by this procedure but 
agglutination will persist. It is often said that a positive "in - saline slide autoagglutination 
test" provides definitive evidence for IMHA and precludes the need for a Coombs’ test 6. 
The majority of pIMHA dogs exhibit marked neutrophilyc leukocytosis with left shift at time 
of diagnosis 
2,6,20
, The mechanism by which this arises is thought to involve tissue necrosis 
and the effect of pro-inflammatory cytokine (e.g. IL - 1, IL - 6 and TNF - α) production by 
activated macrophages on granulopoiesis. A minor percentage are presented with normal 
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leukocyte count, and seldom cases even with leukopenia 
34
. Monocytosis has been reported as 
well
1
.  
Thrombocytopenia can develop in dogs with IMHA because of consumptive coagulopathy 
resulting from disseminated intravascular coagulation, concurrent immune-mediated platelet 
destruction, splenic sequestration of thrombocytes or failure of platelet production (immune-
mediated or chemotherapeutic toxicities)
6,20
. 67-85% of patients show some degree of 
thrombocytopenia
2,11
 (<150x10
3
/L), 45% of which may be severe thrombocytopenia (<50x10
3 
/L), according to one study
2
.  
Other alterations commonly observed regard the coagulation profile of the patients. Dogs with 
IMHA may have a range of hemostatic abnormalities including prolonged prothrombin time 
and activated partial thromboplastin time, elevation of fibrin degradation products, elevation 
in D-dimer, decrease in anti-thrombin activity
17,35
, as well as activation of circulating platelets 
as assessed by increased expression of membrane P - selectin
36
.   
 
Alterations in the biochemical profile often include:  
C- reactive protein increase. Recent study conducted using 28 dogs with pIMHA had found 
that serum CRP concentration is markedly increased in dogs with primary IMHA in 
comparison to healthy dogs. CRP concentration did not differ based on patient survival, but 
might be a marker for long-term monitoring of these patients 
37
. 
Pre-hepatic, hemolysis induced hyperbilirubinemia is very commonly encountered. It is due 
to the fact that the lifespan of red blood cells is greatly reduced, and the rate of hemoglobin 
degradation is therefore increased. Furthermore, studies show that the bilirubin clearance by 
the liver is moderately defective in hemolytic disease, as a result of increased metabolic 
demand in combination of hypoxic centrizonal necrosis 
38
. The hyperbilirubinemia is 
consistent with the clinical findings of icterus in up to 50% of patients 
11
. In addition, 
hemoglobinemia, hemoglobinuria and bilirubinuria are recurrently reported 
2,6,11,20
.  Mild to 
moderately high levels of serum alkaline phosphatase (ALP) and alanine aminotransferase 
(ALT) have also been described
6,20
 and may be a result of hypoxic damage to the liver as well 
as enzymatic induction by endogenous or exogenous corticosteroids.  
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Creatine kinase (CK) increase is not rare in pIMHA dogs, probably as a consequence of the 
hypoxic damage to the tissues containing the enzyme (skeletal muscles, myocardium, brain 
and intestine)
39
,  muscle injury secondary to impaired perfusion, thromboembolic 
complications (including embolic myopathy), repeated IV catheter placement (thrombosis in 
catheters), and SC or IM administered medications. Nonetheless it should be considered as a 
partial pre-analytic artifact, since the hemolysis causes a release of adenylate kinase from the 
red blood cells that could interfere with the CK analytical quantification
40
. 
Hypoalbuminemia is yet another common alteration in the course of the disease
6,20
. It is 
probably due to reduced hepatic protein synthesis during a generalized inflammatory state; a 
negative acute-phase response with down-regulation of albumin synthesis in coordination 
with up-regulation of inflammatory cytokines. Other causes may be proteinuria, enteric 
protein loss, vascular leakage, or hemorrhagic loss. Hypokalemia in pIMHA dogs has been 
described by some authors 
6,20
 and might be caused by the prolonged anorexia and/or diarrhea 
(if present). Nevertheless, it is the most common electrolyte abnormality in clinical practice 
seen in 20% of hospitalized human patients 
41
, therefore having minor specificity to pIMHA 
hematological alterations. 
4.5 Diagnosis of Primary IMHA 
Anemia is a common finding in small animal practice; however, the multitude of potential 
causes can make determining the underlying diagnosis challenging. The diagnosis of IMHA 
proceeds through a series of laboratory tests after identification of compatible clinical history 
and presenting signs. An EDTA - anticoagulated blood sample should be collected for 
hematological examination. This should be examined for the phenomenon of auto 
agglutination that may be observed by rotating the collection tube, or by placing a drop of 
blood on a microscope slide. Auto agglutination may only occur at 4° C, so blood should be 
also refrigerated before making this assessment 
6
. 
Blood smear examination provides instantaneous information about the nature of the anemia 
through observation of RBC morphology. Additionally, many erythrocyte abnormalities that 
cannot be detected by other tests, may be revealed on a blood smear. While examining a 
blood sample of a patient with symptoms compatible with pIMHA, one should examine 
morphological abnormalities as well as erythrocyte regeneration indicators. Spherocytes 
appear smaller than normal RBCs and lack central pallor. In dogs, the presence of spherocytes 
and auto agglutination is highly suggestive of IMHA
42
. Regenerative anemia indicates that the 
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bone marrow is able to respond to the anemia appropriately and that the likely cause of 
anemia is blood loss or hemolysis. The most accurate measurement would be the degree of 
reticulocytosis detected in the patients’ blood. Reticulocytes are red blood cells that have been 
released from the bone marrow before complete extrusion of all RNA and cellular organelles. 
They can be demonstrated in a blood smear using supravital stains such as new methylene 
blue or brilliant cresyl blue. These stains precipitate the RNA in the reticulocyte, staining it 
blue. Reticulocytes stained with new methylene blue appear as erythrocytes with blue 
granules. Reticulocytes are generally not observed for 2 to 4 days aſter an acute episode of 
blood loss or hemolysis. In dogs, the reticulocyte response generally peaks between 4 and 7 
days aſter the insult and starts to decline at 2 to 3 weeks - assuming the underlying cause of 
the anemia has been treated. A reticulocyte count can be performed by incubating a small 
amount of EDTA-anticoagulated blood with an equal amount of a supravital stain such as new 
methylene blue for 10-15 minutes before making a blood smear slide. The number of 
reticulocytes seen per 1000 RBCs is then counted. A high-power field (40× objective) in 
which the RBCs are touching or just overlapping contains approximately 200 cells. The 
number of reticulocytes counted in five such fields is divided by 10 to yield the reticulocyte 
percentage (number of reticulocytes per 100 RBCs)
42
. A corrected reticulocyte count for the 
degree of anemia is calculated by multiplying the reticulocyte percentage expressed as a 
percentage by the ratio of the patient’s PCV to the average normal PCV for the species. 
Additional changes in the RBC indices with regenerative anemia may include macrocytosis 
(high MCV), heterogeneous cell volume (high RDW), and hypochromasia (low MCHC). The 
decreased MCHC reflects normal hemoglobin content in a larger-than-normal cell. On blood 
smear evaluation, RBC morphology shows varying amounts of anisocytosis (variation in 
volume) and macrocytosis (large cells). Nucleated RBC (meta - rubricytes or late rubricytes) 
may also be noted with accelerated erythropoiesis. Polychromatophils are immature RBCs 
that stain blue-purple on Wright-stained blood smears. Polychromasia and reticulocytosis are 
the hallmarks of regenerative anemia that is a consistent features in pIMHA blood 
examinations
6,42
. The absence of a regenerative response after 5 days suggests the possibility 
of bone marrow disease and warrants collection of a bone marrow aspirate and/or core biopsy. 
Platelet numbers will be adequate in primary IMHA, but significant reduction in platelet 
count may indicate concurrent IMT, thromboembolism or DIC
42
 that are a common 
complication of the disease. 
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4.5.1 Coombs' Test  
The Coombs’ test, also known as the antiglobulin test, is used to detect antibody and 
complement on the surface of red blood cells (RBCs). The test was previously considered as 
the gold standard for diagnosis of IMHA, and was recently replaced by flow cytometry. 
Antibodies directed against the RBC surface are often consisted of incomplete fragments that 
sensitize or coat RBC but fail to agglutinate them without addition of potentiators to alter the 
RBC zeta potential or without the addition of antiglobulin reagent. Most incomplete 
antibodies are IgG and are thus detected by anti - IgG serum (as contained in anti- globulin 
reagent). A few IgM antibodies also can be incomplete. These incomplete antibodies produce 
antibody - dependent complement activation; thus antiglobulin reagents are also designed to 
react with complement components on the red cell surface, with the main components 
detected being C4 and C3. Polyspecific reagents for veterinary use typically contain anti - 
IgG, anti - IgM, and anti - C3. Monospecific reagents are also available. 
Two forms of the antiglobulin test are used in veterinary medicine: the direct antiglobulin test 
(DAT) and the indirect antiglobulin test (IAT). The DAT, that detects immunoglobulin and/or 
complement bound directly to RBC, is used to evaluate IMHA patients. The IAT detects the 
presence of unbound antibody in the serum and is not typically used in IMHA cases. In this 
procedure, the addition of antiglobulin reagent to the RBC with bound immunoglobulin or 
complement causes agglutination to occur.  
Nonetheless, the DAT test is a direct assay which is relatively insensitive and at best provides 
only semi-quantitative information on the degree of RBC antibody binding. A negative 
Coombs’ test does not rule out IMHA. Factors that may reduce sensitivity of the assay and 
cause false - negative results include insufficient quantity of antibody or complement on 
erythrocytes, improper antiglobulin to antibody ratio, not incorporating the drug into the test 
that causes a cross-reacting immune response to the drug-red blood cell complex, previous 
corticosteroid treatment greater than 1 week in duration, and improper or warm temperatures 
that disperse cold agglutinins 
43
. Additionally, there will be variations in the methodology 
used by different laboratories. A full Coombs’ test will be performed using a polyvalent 
Coombs’ reagent (that recognizes IgG, IgM and complement C3), but also with antisera 
specific for each of these immunoreactants alone. The read - out for the test is erythrocyte 
agglutination, and the titer of each positive reaction should be determined. The incidence of 
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false negative reactions is greatly reduced when the full test is performed in this manner 
6,44
. 
Interestingly, positive results in the absence of IMHA can also occur. One study described a 
high incidence of C3b bound to RBC in dogs with infections, inflammatory disorders, 
myeloproliferative and lymphoproliferative diseases. Hence, the positive DAT can be useful 
in dogs with signs of hemolytic disease, but needs to be interpreted with caution in other 
conditions
6
. 
In general terms, two broad patterns of Coombs’ reactivity are identified and these have some 
correlation with clinical presentation. The most commonly recorded pattern involves an IgG 
antibody that may be present with IgM and/or C3, and that reacts equally at 4° C and 37° C. 
This pattern frequently correlates with disease of chronic onset and is compatible with 
extravascular RBC removal. The second pattern which manifests C3b and IgM reactivity has 
been reported with higher frequency in secondary IMHA. IgM reactivity at 4°C was also 
more often seen in the dogs with secondary IMHA, yet clinical significance of cold 
agglutinating antibodies is widely debated. There is a belief that they are less significant as 
they are rarely active at body temperature, but few studies have investigated the complete 
temperature gradient of the reactivity of these immunoglobulins 
45
. The latter pattern of 
Coombs’ reactivity is more often associated with sample auto agglutination, intravascular 
hemolysis and acute onset, severe clinical disease. Although low titers or the presence of 
complement alone on the RBC surface are often thought to be more consistent with secondary 
IMHA than pIMHA, a recent study has not confirmed this 
46
. 
4.5.2 Direct Immunoluorescence Flow Cytometry 
 Direct immunofluorescence flow cytometry (DIFC) can be used to detect anti-RBC 
antibodies and it is considered by some authors to be more sensitive and quantitative assay for 
the detection of anti-RBC antibodies than the Coombs' test 
47
. The use of flow cytometry to 
detect anti-RBC antibodies was reported previously in 2 studies conducted on a small number 
of dogs with IMHA. The majority of dogs in those studies had IgG antibodies, whereas a few 
animals had only IgM antibodies
43,48
. In another study, flow cytometry was also compared 
with the Coombs’ test and found it to be more sensitive in dogs with IMHA (100% versus 
58%). In contrast, the Coombs’ test had better specificity than the DIFC assay (100% versus 
87.5%, respectively)
43
. Therefore, DIFC is currently the most frequently used test for the 
diagnosis of IMHA. 
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Flow cytometry measures specific characteristics of cells as they flow through a flow 
chamber, and through the focused beam of a laser. The cells can be fluorescently labeled, 
typically with a fluorescently conjugated antibody, or can be analyzed unlabeled. When 
labeled cells pass through the laser, the laser light activates the fluorophore at the excitation 
wavelength, and the emitted fluorescence as well as the light scattering properties of each cell 
are detected. The intensity of the emitted light is directly proportional to the antigen density of 
the cell. More specifically, using this technique for the detection of IgG, IgM fragments and 
components of complement (C3) on the cell's surface, RBCs are washed and incubated with 
fluorescein isothiocyanate (FITC) - labeled sheep - antidog IgG, FITC - labeled goat - antidog 
IgM, or FITC - labeled goat - antidog C3. Cells are then re-washed, re-suspended and 
fluorescence is analyzed in a flow cytometer 
6,44
. The main disadvantage of this test is to 
necessitate the availability of a flow cytometer in the laboratory
6,48,49
. 
 
4.5.3 Gel Microcolumn 
A recent innovation is the development of a tube - based test designed for in - practice use. 
The test is presented in the form of a small plastic card within which there are six columnar 
tubes with an over- lying reservoir of wider diameter. The tube contains a gel matrix 
impregnated with rabbit polyvalent DAT- reagent specific for either dog or cat. Separate cards 
comprised tubes containing only the gel matrix without antibody are used as a negative 
control. Using the diluent supplied by the manufacturer a 0.8% RBC suspension is prepared 
and 50 μl of this suspension is pipetted into the reservoir above the gel. The card is then 
centrifuged in a purpose-designed centrifuge. Following centrifugation, the tubes are 
examined to determine the distribution of the RBCs. Red blood cell agglutinates become 
trapped and remain stable in the gel, while free RBCs pass through and form a button at the 
bottom of the tube 
45
. In the negative test the cells are pelleted at the bottom of the tube. 
Where cells were distributed within the cell matrix the test result is considered as weak 
positive. Where cells are retained at the top of gel the test it is regarded as positive. A study 
conducted in 2012 on 247 canine patients had found that the gel test identifies fewer positive 
samples than the DAT. The positive DAT samples that were missed by the gel test (n = 27) 
were mainly from dogs with secondary IMHA (n = 20). Only three cases of idiopathic IMHA 
were missed. Since the gel test is faster and more easily performed than the conventional 
DAT it might be used as a screening test for IMHA, but if negative, IMHA cannot be 
excluded and an extended DAT should be performed 
45
. Similar results were reported by other 
25 
 
authors 
50
, but unfortunately for the time being the Gel is not commercially available for dogs 
45,50
.  
 
4.5.4 Immunochromatographic Strip 
The Strip is an innovative and entirely new approach to immunohematology, which has 
already proven invaluable for canine and feline blood typing 
51
 and is being developed for in-
clinic or laboratory DAT by the same manufacturer (QUICK TEST DAT
©
, Alvedia). It 
utilizes an immunochromatographic strip with impregnated reagent M to bind antiglobulin-
coated RBCs as they diffuse to the top of the strip. It is therefore, a non-agglutination-based 
test. A recent study had compared the Strip result to other DAT methods 
50
, in the author's 
experience, the Strip was easy to perform, but the resulting band strengths were frequently 
weak, which could make interpretation a little difficult. The Strip results, which included the 
weak bands, correlated well with those of other DAT methods and thus can readily be used as 
an in-clinic screening test. 
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4.6 Coagulopathy - A Common Complication of  IMHA 
Thromboembolic disease is a major concern affecting survival in dogs with IMHA. It is likely 
that hemolysis contributes to the prothrombotic state. Thrombosis occurs in both veins and 
arteries, with pulmonary thromboembolism (a venous thrombus) occurring very commonly 
52
. 
The majority of dogs with idiopathic IMHA are in a hypercoagulable state at the time of 
diagnosis. A recent study used recalcified unactivated thromboelastography (TEG) and other 
coagulation assays over a 5 day period to assess the coagulation status of 30 canine patient 
diagnosed with IMHA 
24
. Based on TEG, dogs with IMHA were significantly 
hypercoagulable vs. controls and over the 5 day period, 3/4 of the TEG parameters reflected 
progressively increased clotting kinetics. The 30 day survival of these patients was 80% and, 
at hospital admission, the TEG maximum amplitude (MA) was significantly higher in 
survivors than non-survivors. Relative hypocoagulability identified by TEG at initial 
assessment was found to be a negative prognostic indicator 
24
. 
To adequately understand the prothrombotic mechanisms involved in IMHA 
hypercoagulability state, one should first reflect the complex physiological process of 
hemostasis. 
Physiologic hemostasis 
Primary hemostasis refers to the formation of the platelet plug, while secondary hemostasis 
refers to activation of the coagulation cascade and the formation of a fibrin network. During 
normal hemostasis, activation of coagulation and platelets occurs simultaneously. To consent 
proper hemostasis, a platelet-fibrin clot is formed via 3 overlapping phases, initiation, 
amplification, and propagation. Endothelial damage initiates the formation of a platelet plug 
through binding of platelets to subendothelial collagen, which is facilitated by vonWillebrand 
factor (vWf). Tissue factor (TF) within the blood vessel wall simultaneously activates the 
coagulation protease cascade. The extrinsic cascade is comprised of TF and factor VIIa. The 
extrinsic cascade initiates coagulation during normal hemostasis and in many prothrombotic 
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states. Tissue factor is normally absent from the vascular space, being expressed by cells 
surrounding blood vessels such as pericytes and subendothelial fibroblasts. The initiation 
phase of coagulation is localized to TF-bearing surfaces. During this phase, coagulation is 
initiated by exposure of TF to plasma due to endothelial damage, or expression of TF on the 
surface of activated endothelial cells, monocytes, or microparticles. Circulating microparticles 
are derived from cell membranes of RBCs, platelets, megakaryocytes, endothelial cells, 
neutrophils, and monocytes. They express cell surface molecules that are derived from their 
cell of origin, and are able to interact with, and induce cell signaling in other cell types, 
including the endothelium. Evidence suggests that activated platelets release 
phosphatidylserine (PS) exposing microparticles. Microparticles derived from monocytes and 
endothelial cells and possibly platelets also express TF. Regardless of its source, exposure of 
TF to plasma factor VII/VIIa initiates coagulation and results in the production of a small 
amount of thrombin (also referred to as factor IIa). The amplification phase of coagulation 
occurs mainly on platelets. Thrombin activates platelets, and platelet-associated factor V. 
Factor Va acts as a cofactor for factor Xa. Together they form the prothrombinase complex 
that converts prothrombin to thrombin with the result of the production of more thrombin.  
The intrinsic pathway consists of high-molecular-weight kininogen, prekallikrien, and the 
serine proteases factor XII, factor XI, factor IX, and factor VIII. Thrombin activates factor 
VIII and factor XI. The propagation phase is driven by thrombin activation of the intrinsic 
pathway downstream of factor XII, and is thought to occur primarily through thrombin- 
induced activation and formation of the tenase complex (factors VIIIa- IXa) and factor XIa. 
The TF-factor VIIa complex also activates the intrinsic cascade through activation of factor 
IX. Formation of the tenase complex, and subsequent further activation of factor X and V, 
results in further generation of thrombin. Large amounts of thrombin are produced in the 
propagation phase. Thrombin catalyzes the conversion of fibrinogen to fibrin, and activates 
the transglutaminase factor XIII which then cross-links fibrin and stabilizes the clot. In 
addition to its role in the propagation of the coagulation cascade and formation of fibrin, 
thrombin is a potent activator of platelets and endothelial cells via cleavage of protease-
activated receptors. Platelets and other cells release microparticles that enhance clotting by 
providing a membrane surface for the assembly of the prothrombinase and tenase complexes. 
Thus, platelets and the clotting cascade work together in the generation of a blood clot.  
The major inhibitor of the extrinsic pathway is tissue factor pathway inhibitor (TFPI). TFPI is 
expressed by endothelium and binds to its surface. There are also small amounts of TFPI in 
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the circulation. Another anticoagulant expressed by activated endothelium is 
thrombomodulin. When thrombomodulin binds thrombin, its substrate specificity changes and 
it becomes an anticoagulant protein by activating protein C. Activated protein C with its 
cofactor, protein S, cleaves and inactivates factors Va and VIIIa. Antithrombin (AT, formerly 
antithrombin III) inhibits factors Xa, IIa, VIIa, IXa, XIa, and XIIa. The activity of AT is 
dramatically increased after binding heparan sulfate, which is expressed on the surface of 
endothelial cells. Fibrinolysis occurs gradually after clot formation. Activated endothelium 
and monocytes produce tissue plasminogen activator (tPA), which converts plasminogen to 
plasmin. Annexin A2 on the surface of endothelial cells facilitates the localization of tPA and 
plasminogen in close proximity to each other. Tissue plasminogen activator activity is 
dramatically increased for plasminogen bound to fibrin, thus localizing plasmin production to 
the region of a blood clot. Plasmin is an endopeptidase that cleaves fibrin which destabilizes 
the clot and results in the production of fibrin degradation products. Plasmin also inactivates 
factors V, VIII, IX, and XI, cleaves complement component C3, enhances conversion of 
factor XII to XIIa and conversion of prekallikrein to kallikrein. Inhibitors of plasmin 
generation and activity include plasminogen activator inhibitors, α - 2 antiplasmin, α - 2 
macroglobulin and other protease inhibitors. Increased procoagulant, decreased anticoagulant, 
and impaired fibrinolytc activity may shift the hemostatic balance toward thrombosis 
52
. 
 
4.6.2 The Pathophysiology of Thrombosis in IMHA 
Thrombosis is defined as the pathologic formation of a blood clot inside a blood vessel. 
Thrombosis can occur in either arteries or veins. Importantly, the pathogenesis of the 
generation of an arterial or venous thrombus differs. Arterial thrombi form primarily as a 
consequence of platelet activation under high blood flow conditions in arteries and arterioles, 
and are described as “platelet rich.” Venous thrombi form under low blood flow in veins and 
venules and are fibrin rich due to the activation of coagulation. Pulmonary thromboembolism 
(PTE), thought to occur due to the release of venous emboli, is very common in dogs with 
IMHA
52
. In addition, IMHA is a common underlying disease in dogs with cranial vena cava 
thrombosis. In recent studies, 80 – 100% of necropsies performed on dogs who died from 
IMHA revealed evidence of thromboembolism 
17,20
 . Thromboemboli were located in the 
lungs, heart, liver, spleen, kidney, lymph nodes and pituitary gland. In many dogs, emboli 
were found in multiple organs
17
.  Thus it appears that IMHA may cause generalized 
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thromboembolic disease of both veins and arteries, with PTE (a venous thrombus) being a 
very common clinical manifestation of thrombosis. 
The presence of both venous and arterial thrombosis suggests that disregulation of both 
coagulation and platelets occurs in dogs with IMHA. Indeed, dogs with IMHA exhibit 
excessive platelet activation 
36,53
 and activation of coagulation is evidenced by the common 
findings of decreased AT, thrombocytopenia, prolongation of activated partial thromboplastin 
time (APTT) and prothrombin time (PT), elevated D-dimers 
17,20,24,54
 and the finding of 
widespread fibrin deposition at necropsy. Many dogs with IMHA meet the clinical criteria for 
disseminated intravascular coagulation (DIC). Liberation of RBC stroma may be one trigger 
for DIC during hemolysis
17
.  Interestingly, the presence of DIC was not a risk factor for 
thrombosis in one study 
17
. However, prolongation of  PT, suggesting consumption of factors 
in the extrinsic pathway, is associated with mortality 
55
. 
 
The convoluted mechanism that leads to hypercoagulability in IMHA dogs was recently 
described by Kidd and Mackman 
52
. According to the authors, the extrinsic pathway plays a 
role in the formation of thromboemboli. Increased tissue factor (TF) expression may initiate 
intravascular coagulation in pathologic states associated with thrombus formation. 
Pathologically increased TF originates mainly from endothelial cells. Studies of humans and 
laboratory animals suggest that free hemoglobin may cause TF expression in these cells. Free 
hemoglobin results in the scavenging of nitric oxide (NO)
56
, reduced levels of NO may 
contribute to increased TF expression in the pulmonary endothelium of mice with hereditary 
sickle cell anemia and human endothelial cells in vitro
57,58
 .  
Moreover, inflammatory cytokines can also induce expression of TF on the surface of 
endothelial cells. Monocytes are activated by erythrophagocytosis and release inflammatory 
cytokines that induce TF expression. In fact, a recent study showed that cytokines associated 
with macrophage and monocyte activation were significantly elevated in dogs with IMHA 
who died in comparison to survivors 
59
.  
Microparticles (MPs) which carry superficial phosphatidylserine (PS) and express TF might 
also play a role in thrombosis in human patiants
54
. MPs are derived from blebbing (or 
protrusion) of the cytoplasmatic membrane of many cell types, and are released upon cell 
activation or injury. They are then cleared primarily by the reticuloendothelial system
54,60,61
 . 
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Activation and injury of cells also cause plasma membranes to lose phospholipid asymmetry 
and expose anionic phospholipids, such as PS, on their surface. PS exposure provides a 
negatively charged docking site for tenase and prothrombinase complexes of the coagulation 
cascade
62
. Damaged and senescent RBCs also express PS on their surface and form 
procoagulant MPs. Triggers for increased RBC micro vesciculation include complement 
attack, oxidative injury, and even stress - conditions that are present in dogs with IMHA
54
. 
Reticulocytes also express increased levels of cell surface PS, and it has been postulated that 
reticulocytosis contributes to the risk of thrombosis in hemolytic disease 
63
. Auto 
agglutinating RBCs may also contribute to the direct occlusion of vasculature and worsening 
thrombosis. Auto agglutination is common in dogs with IMHA and is associated with 
decreased survival in some studies 
2,20
. 
Platelets also play an important role in the formation of thrombus since sequestration of NO 
by plasma hemoglobin results in platelet aggregation
52
. Furthermore, loss of asymmetry and 
exposure of PS on the outer surface occurs after platelet activation. Platelet MPs exposing PS 
are 50- to 100-fold more procoagulant than activated platelets. MPs from platelets have been 
demonstrated to be 100% higher in dogs with IMHA than in healthy dogs 
53
.  
Recent study preformed on 32 dogs demonstrated that some dogs with IMHA have increased 
procoagulant activity associated with phosphatidylserine-positive (PS+) and tissue factor-
positive (TF+) MPs in peripheral blood. However, in that study the cellular resource of MPs 
was not identified, there was no standardization of therapeutic protocols and no exclusion 
criteria ware established on the base of concomitant disease. Therefore, larger studies with 
comprehensive underlying disease screening and standardized medical treatment to determine 
whether MPs can be used as markers of thrombotic risk, and studies to determine the cellular 
origin of MPs in dogs with IMHA are warranted 
54
. 
The excessive activation of coagulation in dogs with IMHA is accompanied by decreased 
levels of anticoagulants. Decreased AT activity is common in these patients. Decreased AT 
likely contributes to the prothrombotic state, although no association with AT activity and 
mortality was found in one study
35
. Impaired fibrinolysis, characterized by increased levels of 
plasminogen activator inhibitors, antibodies to annexin A2 and other mechanisms, contribute 
to the prothrombotic state in some thrombotic and autoimmune diseases in people 
64
. 
Antiphospholipid-antibody-syndrome (APLA) is a common complication of SLE in humans 
65
. It has been suggested that a similar mechanism may in part be associated with the 
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enhanced platelet aggregation and depresses regulation of the coagulation pathways. 
However, in a recent case series only two of 20 dogs had evidence of anti - phospholipid 
activity
35
. Whether decreases in inhibitors of coagulation other than AT, or an imbalance of 
the fibrinolytic pathways may occur in human or canine patients with IMHA has not been 
investigated. 
 
Therapy and supportive measures used in the treatment of dogs with IMHA may also 
contribute to thrombosis. Microparticles are cleared by phagocytic cells in the spleen that 
contain receptors for PS or opsonins on the microparticle surface, such as complement 
66
. It is 
possible that immunosuppressive and immunomodulatory therapy directed at inhibition of 
phagocytosis in patients with IMHA might increase levels of circulating microparticles and 
contribute indirectly to the prothrombotic state. Indeed, splenectomy and human intravenous 
immunoglobulin G (hIVIG) are associated with an increased risk of thrombosis in people, and 
hIVIG administration is prothrombotic in normal dogs 
67,68
. However, in one retrospective 
study describing splenectomy as an adjunctive therapy for 10 dogs with idiopathic IMHA, no 
clinical signs of thromboembolic events were observed after splenectomy was performed and 
9/10 dogs were alive at 30 days 
69
.  
Drugs used in the treatment of IMHA may exacerbate thrombosis by other mechanisms. 
Glucocorticoids  increase circulating levels of some coagulation factors and decrease 
fibrinolysis, although this is yet to be proven in human or canine IMHA patients 
52
. 
Thrombotic events are a well-known complication of cyclosporine use in people
70
. Whether 
the use of glucocorticoids or cyclosporine in dogs with IMHA contributes to the risk of 
thrombosis is not known. Other supportive measures commonly used in the treatment of dogs 
with IMHA, such as the use of IV catheters, have been associated with thrombosis in people 
and in dogs 
71,72
. Cage confinement and prolonged recumbency may also exacerbate 
hypercoagulability 
20
.  
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Chapter five: Prognostic Factors and Outcome 
 
5.1 Mortality Rates and Prognosis for Primary IMHA Patients  
Measurement and evaluation of prognostic factors has the potential to improve the clinical 
management of cases of IMHA in dogs and to allow resources to be targeted appropriately 
.The current literature well-describes prognostic factors for dogs with IMHA, but these differ 
widely among studies. The studies consider mainly hematologic, biochemical, and clinical 
variables as potential prognostic factors and several studies evaluate the effect of different 
treatment protocols on survival
73
. 
It is clear that canine IMHA must be regarded as a severe disease. Reported mortality rates for 
idiopathic IMHA range from 22 to 80%, with significantly increased mortality early in the 
disease course
74
. The most recent study evaluating prognostic indicators and mortality rates 
reported a 43,9% mortality with a survival range of 2–96 days; mean 19 days; median 7.5 
days 
31
. However the group of animals used for the latter study was quite small and consisted 
of only 41 dogs. Considering a larger scale study performed by Piek et al. at 2008 using 149 
dogs, the estimated half-year survival for the whole group was 72.6%. The estimated half-
year survival rate for the 96 dogs that survived the 1st 14 days was 92.5%, thus confirming 
the hypothesis of a higher mortality rate with chronological proximity to the onset of the 
disease.  
 
By contrast, some dogs with IMHA make excellent recovery with appropriate supportive and 
immunosuppressive therapy, but remain at risk for a disease relapse. There is often very rapid 
clinical and hematological response to therapy in such patients; however, serial monitoring of 
the Coombs’ test has revealed striking persistence (for many months) of RBC - bound 
autoantibody in many cases. Re-occurrence of the disease is defined as a decrease in 
hematocrit after an initial improvement of full recovery
2
. Relapses may occur months or years 
after the initial episode (one report indicated a median of 112 days ranging between 32 and 
1750 days 
2
) and are often more severe, resulting in death. Relapse in clinical disease is 
reported in 15% of dogs that survived beyond 60 days. During this time interval, treatments 
33 
 
had either been discontinued or were on a tapering course. Relapse was as likely to occur 
while on a tapering course of medication as after treatment was discontinued
20
.  
Other manifestations of autoimmunity may appear or develop in dogs recovered from IMHA, 
sometimes several years later. For example, dogs may present with IMT (and no anemia) 
subsequent to IMHA (without thrombocytopenia). SLE and immune - mediated skin disease 
are also reported sequels. 
Therefore, recovery from IMHA necessitates regular monitoring for the life of the patient. 
Hematological monitoring is the most cost - effective means; it is recommended that a PCV 
be performed every 2 weeks throughout the course of treatment, extending for 6 – 12 months 
after withdrawal of therapy. In dogs recovered from IMHA associated with vaccination, care 
should be taken with administration of subsequent booster vaccines. A risk - benefit analysis 
should be conducted in consultation with the client. Measurement of serum antibody titre to 
core virus vaccine may be performed to support any decision not to re-vaccinate, but where 
re-vaccination is required, it is recommendable to use of a product from a different 
manufacturer and a product with the longest possible duration of immunity is advised. There 
is, however, little clear evidence that booster vaccination induces relapse of disease or disease 
of greater severity 
6
. 
 
5.2 Prognostic Factors 
Factors associated with reduced survival in the large case series of Weinkle et al., Carr et al., 
Goggs et al. and Piek et al. included: 
(1) Auto agglutination; was more common in dogs that died or were euthanatized during 
initial hospitalization, compared with dogs that survived to discharge (36/37 [97%] vs 82/114 
[72%])
20
.  
(2) Thrombocytopenia; lower platelet count was associated with worst outcome in three of the 
studies. 
(3) Hyperbilirubinemia; all four studies indicate increased serum TB as a poor prognostic 
factor.   Two of which refer to a lower rate of serum TB concentrations (> 1.5 mg/dL ; 
reference range, < 0.3 mg/dL). This serum concentration is the concentration above which 
hyperbilirubinemia is manifested clinically as jaundice. Most dogs that died had jaundice, 
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whereas 50% of surviving dogs did not
2,20
. Another study refers to a higher TB serum 
concentration of  >5mg/dL
17
. 
(4) Hypoalbuminemia; associated with poor prognosis in two studies, but in a lower degree of 
significance 
17,20
. 
(5) Band neutrophilia; a presence of  ≥ 3,000 cells/µL was indicated as a poor prognosis 
indicator by Weinkle et al. and Piek et al. This finding may reflect ischemic or hypoxic tissue 
necrosis accompanying severe anemia 
2,20
. 
(6) Hypokalemia; Although an association between hypokalemia (serum potassium 
concentration < 3.5 mEq/L) and an increased rate of mortality has not been reported, the 
association between critical illness and hypokalemia is not novel. Hypokalemia promotes 
vascular constriction and may increase the risk for vascular and thromboembolic 
complications
20
.  
(7) Increased serum urea concentration; Reported by by Piek et al. and Goggs et al. defined as 
one of the four main predictors of mortality in dogs with idiopathic IMHA 
2
. 
 
 
5.3 Scoring Systems 
Many attempts have been made to link clinical pathologic changes with the prognosis in 
patients with IMHA, and although individual studies have detected associations between 
specific laboratory criteria and outcomes, few prognostic indicators are consistently 
reproducible in multiple studies
75
.  
Scoring schemes are routinely used in human medicine to predict patient outcome and 
compare treatment protocols. So far two different grading scales that predict the outcome of 
the disease in dogs with IMHA. The canine hemolytic anemia objective score (CHAOS) and 
the Tokyo 
76
 score were developed to predict the survival of dogs with hemolytic anemia. 
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Table 5.1 Instruction for calcolation of illnes severity scores by two scoring systems; in both scales 
the prognosis improves with the increase of the score. 
Canine hemolytic anemic objective score (CHAOS).  
 Age (year) If ≥7 score 2, otherwise score 0 
Temperature (°F)         If ≥102.0 score 1, otherwise score 0 
Agglutination If present score 1, otherwise score 0 
 Albumin (g/dL)               If <3.0 score 1, otherwise score 0 
Bilirubin (mg/dL)           If ≥5.0 score 2, otherwise score 0 
Total                                 Maximum score 7 
Published by Whelan et al. 2006  
Tokyo score   
 Sex                            Male score 1, Female score 0 
Season                               Apr-Sept score 1, Oct-Mar score 0       
Packed cell volume (%)                           If <20 score 1, otherwise score 0 
Platelet count ( 103/µL)                              If <200 score 1, otherwise score 0 
Total protein (g/dL)                           If <6.0 score 1, otherwise score 0 
Total                                       Maximum score 5 
Published by Ishihara et al. 2009  
  
 
Alternatives to these disease-specific illness severity scores that might be easier to estimate 
are the American Society of Anesthesiologists (ASA) health classification and the presence or 
absence of markers of a systemic inflammatory response syndrome (SIRS). The ASA 
classification is typically used to evaluate patient risk for anesthesia, but the classification is 
easy to apply and has been used as a marker of disease severity in other canine populations. A 
recent study preformed in 10 referral veterinary centers in the UK has evaluated the 
previously mentioned illness-severity scores 
77
. The Study found no association between the 
Tokyo score and the mortality either at time of discharge or within 30 days. The CHAOS 
univariate analyses, when dichotomized as <3 or ≥3, was associated with death in hospital and 
death within 30 days of admission. The authors also found that ASA classification ≥3 was 
also associated with death, suggesting the subjective assessment of experienced clinicians can 
be a reasonable gauge of illness severity in IMHA. Markers of kidney function, bilirubin 
concentration were likewise identified as independently associated with outcome. Therefore, a 
multivariate model combining illness severity scores and the above mentioned 
36 
 
clinicopathological data was established. The new model correctly predicted outcome at 
discharge in 82% cases 
77
.  
It is hoped that the identification of "at high risk" patients will allow early intervention and 
resource management to improve the clinical decisions making and the outcome of this 
frustrating and common disease. 
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Chapter six: Immunosuppressive and Supportive Care 
 
Immune-mediated diseases represent some of the most frustrating types of disorders that are 
diagnosed and treated in veterinary medicine. Drug-induced immunosuppression is an attempt 
to control the aberrant immune response against self antigens, but the immunosuppression can 
result in sepsis or other unacceptable adverse effects. If the pathophysiology of immune-
mediated and autoimmune disease is considered, the immune response can be divided into 
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several components and attempts can be made to selectively deal with each component 
separately. The components of the immune response that can be manipulated by therapy 
include antibodies, effector cells, mononuclear phagocytic system and clinical manifestations 
of disease 
3
. In true autoimmune responses such as in Auto Immune Hemolytic Anemia, an 
autoantibody (antibody with activity against self antigens) is the inciting cause of the 
immunologic damage. As formerly mentioned in chapter 3, these autoantibodies can either 
cause intravascular hemolysis by Complement - induced lysis, or, more frequently membrane 
damage by ADCC (antibody dependent cell-mediated cytotoxicity) and complete 
phagocytosis of the cell primarily in the liver and spleen. It is therefore apparent that immune-
modulatory treatment should be directed at suppressing these specific mechanisms of the 
immune response.  
For the time being, the majority of clinicians use a non-selective immune-suppressive 
approach. This nonselective immune-suppressive approach has several negative aspects. 
Because conventional therapy suppresses protective as well as destructive immune responses, 
the individual is predisposed to infectious diseases. Death due to overwhelming infection is a 
risk of immunosuppression. In addition, adverse effects of currently used immunosuppressive 
agents are considerable. Glucocorticoids commonly cause iatrogenic hyperadrenocorticism 
and may possibly be associated with pulmonary thromboembolism. Cytotoxic agents can 
induce significant bone marrow suppression as well as gastrointestinal upset. Therefore, 
nonselective immunosuppression is a crude approach, and the current therapeutic strategies 
should be improved
3
. In the following chapter conventional immuno-supressive agents will be 
presented along side with some of the new non conventional agents not yet applicable for 
veterinary use. 
 
 
6.1 Immunosuppressive treatment  
 
6.1.1 Glucocorticoids 
Glucocorticoids (GC) act primarily by binding to a cytosolic glucocorticoid receptor (GR), 
which then translocates to the nucleus, binding specific DNA sequences (glucocorticoid 
responsive elements) where they act to enhance or inhibit transcription of corresponding 
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genes 
78
. Recent evidence suggests that more rapid effects are mediated through GRs 
influencing intracellular signalling, non-specific interactions with cell membranes and 
specific interactions with membrane-bound receptors. Anti-inflammatory effects of 
glucocorticoids relate to the stabilization of cell membranes of granulocytes, mast cells and 
monocytes-macrophages and inhibition of phospholipase A2 (thereby preventing release of 
the arachidonic acid metabolites of the cyclooxygenase and lipoxygenase pathways). In 
addition, glucocorticoids prevent release of the pro-inflammatory cytokines IL-1 and IL-6. 
Effects on complement and rapid down-regulation of Fc receptor expression on macrophages 
reduce phagocytosis of opsonised red blood cells. The latter could explain much of the 
reported early efficacy of glucocorticoids in treating IMHA.  
Immunosuppressive effects in dogs are less clear from published studies but may include 
reduction in antigen processing and presentation by effects on macrophages and dendritic 
cells, direct suppression of T cell function (including T cell help for B cells) and reduced 
affinity of antibody to cell membrane epitopes
33
.  
The widespread distribution of GRs and the vast number of genes affected by GR ligation 
goes some way to explain the severity and wide range of side effects caused by systemic 
administration of glucocorticoids 
79
. Side effects from long-term high dose GC treatment 
include serious endocrine alterations. Decreased beta-cell insulin production and insulin 
resistance may lead to diabetes mellitus. Prolonged suppression of adrenocorticotropin levels 
leads to atrophy of the adrenal cortex and secondary adrenal insufficiency
80
. Iatrogenic 
Cushing syndrome will eventually develop in all patients undergoing prolonged GC therapy
80
 
and includes:  polydipsia, polyuria with reduced urine specific gravity
81
, atrophy of epidermis 
and dermis, decreased fibroblast proteo-synthesis that results in wound healing and scaring 
disorders, catabolic effect on skeletal muscle protein, muscle atrophy
80
 and lethargy. The most 
predominant findings on biochemical are elevated alkaline phosphatase and alanine 
transferase ; hypercholesterolemia ; hyperglicemia; elevated aspartate transaminase; and 
elevated triglycerides
81
 .In one study the mean time to complete remission of GC adverse 
effects was 12 weeks 
81
.  
 
Currently, prednisolone (prednisone), methylprednisolone and dexamethasone are the most 
widely used glucocorticoids for systemic effect. Prednisolone has an anti-inflammatory 
potency roughly equal to hydrocortisone, whereas methylprednisolone and dexamethasone are 
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approximately 5 and 30 times more potent, respectively. Prednisolone and 
methylprednisolone have an intermediate duration of action and dexamethasone has a long 
duration of action relative to hydrocortisone. Doses of prednisolone up to 0,5 mg/kg twice 
daily are considered anti-inflammatory and higher doses immunosuppressive. In reality, there 
is likely to be a continuum of effect due to the large number of cellular processes influenced 
by glucocorticoids and such a division is somewhat arbitrary. Immunosuppressive protocols 
invariably involve tapering the glucocorticoid dose down to zero (according to clinical effect) 
over several weeks or months. Glucocorticoids should not be abruptly discontinued due to 
time required for resolution of the iatrogenic suppression of the hypothalamic- pituitary-
adrenal axis
33
.  
It is common to combine a cytotoxic drug with glucocorticoids in the therapy of IMHA. The 
rational behind this is obvious when one looks at the various aspects of the immune response 
suppressed by each drug. The addition of a cytotoxic drug usually allows reduction in dosage 
or more rapid tapering of the dosage of glucocorticoids 
3,2
. Nevertheless this is yet to be 
demonstrated scientifically since some authors offer disputable results 
73,82
. Further work 
should be directed at examining the effects of treatment regimen and combination of drugs on 
outcome, using larger study groups, more standardized protocols of treatment and uniform 
patient inclusion and exclusion criteria. 
 
 
6.1.2 Azathioprine 
Azathioprine is a cytotoxic synthetic imidazole derivative of 6-mercaptopurine (6MP). Both 
are thiopurines, which interfere with purine synthesis and result in production of fraudulent 
nucleotides. Hence, DNA and RNA syntheses are inhibited, and mitosis and cellular 
metabolism is disrupted. Two studies found that azathioprine does not reduce serum 
immunoglobulin concentrations
83,84
. Rinkardt et. al also reported no reduction in circulating 
blood lymphocytes or specific subsets of these cells. However, these observations were only 
made at 14 days after commencing of therapy, and it is generally accepted that azathioprine 
has a “lead-in time” of 11 days before having clinical effect. The main effects of this drug are 
thought to be on Cell Mediated Immunity (CMI) with a reduction in lymphocyte number and 
T cell-dependent antibody synthesis. Azathioprine has long been used in combination with 
glucocorticoids, with which it is thought to have a synergistic effect, to allow more rapid dose 
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reduction or tapering of glucocorticoids (the “glucocorticoid sparing” effect). Speed of onset 
of immunosuppression induced by azathioprine alone is reported to be variable. One study has 
documented a reduction in T cell blastogenic response to mitogens at 7 days 
84
, whereas 
another suggested a lag period of 3 to 5 weeks 
85
. Azathioprine has been extensively used in 
management of canine immune-mediated disease, with relatively low cost and good 
tolerability making it an attractive choice. A few large retrospective studies lend limited 
support to its use but there are no prospective controlled studies.  
The principle adverse effects of azathioprine are myelosuppression resulting in 
thrombocytopenia, acute pancreatitis, hepatopathy and gastrointestinal distress
85,86,87
 . Safety 
and efficacy of azathioprine therapy in dogs might be refined by considering drug metabolism 
in more depth: azathioprine is initially converted in the liver and other tissues to 6MP. 
Thiopurine methyltransferase (TPMT) is an important enzyme in the metabolism of 6MP and 
can be measured in canine erythrocytes. Variation in TPMT activity correlates with clinical 
outcomes in human patients receiving azathioprine, with high TPMT activity associated with 
reduced efficacy and low TMTP activity associated with increased risk of bone marrow 
toxicity. Notably, significant breed-related variation in TMTP activity has been documented 
in dogs, with TMTP activity being much lower in giant Schnauzers and much higher in 
Alaskan Malamutes than in other breeds 
88
. Six single-nucleotide polymorphisms have been 
found to account for much of the variation in TMTP activity in the canine population 
89
. 
Standard treatment protocol of Azathioprine  is 2 mg/kg/day PO for dogs weighing under 20 
kg. The daily azathioprine dose in dogs of 25, 30, 40, and 50 kg can be maximized at 45, 50, 
60, and 70 mg, respectively 
2
, commencing at 2mg/kg SID 
6
. 
 
6.1.3 Cyclophosphamide 
Cyclophosphamide is a cytotoxic alkylating agent that cross-links DNA, preventing its 
separation. It is toxic to resting and dividing cells, particularly proliferating lymphocytes. It 
suppresses CMI and humoral immunity and was shown to suppress the function of B 
lymphocytes preferentially as compared with T lymphocytes in guinea pigs and presumably in 
humans, but non in canines
90
. Paradoxically, Cyclophosphamide increases the severity of 
inflammatory disease and reduces regulatory T cell numbers in some experimental rodent 
models. The latter study found that the drug aggravated features of allergic inflammation by 
reducing expression of suppressive cytokines due to toxicity of regulatory T cells 
91
. 
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Cyclophosphamide has been used extensively in the dog for management of primary IMHA 
and sporadically for other immune-mediated diseases. It has been proposed that the primary 
indication for cyclophosphamide therapy in the dog should now be for cancer therapy. As for 
most other immunosuppressive agents, there is a lack of published efficacy data. Studies 
suggesting increased morbidity and the increased incidence of serious adverse effects of 
cyclophosphamide do not justify its use as an immunosuppressive agent. The toxic effects of 
the drug include: leukopenia, anemia, hemorrhagic gastro-enteritis and cystitis, adrenal 
insufficiency and liver function alterations
86
.   
Despite the fact that cyclophosphamide is still in common use as an immune-suppressive drug 
for the treatment of pIMHA, recent studies have demonstrated that it has little if no beneficial 
value. According to a randomized controlled prospective clinical trial completed in 2003, the 
addition of cyclophosphamide to glucocorticoid therapy did not accelerate the resolution of 
spherocytosis or the resolution of a positive Coombs’ test result, suggesting that 
cyclophosphamide had no additional effect on reducing the production of anti-erythrocyte 
antibody compared to prednisone alone
92
. Furthermore, two retrospective studies suggested 
that the use of this drug resulted in an increased mortality compared with other interventions 
82,93
. Based on this evidence, some authors do not consider the use of cyclophosphamide to be 
warranted when alternative products are available
73
. 
The standard treatment protocol with cyclophosphamide is the following: either 50 mg/m2 
body surface area PO q24h for 4 days a week or 200 mg/m2 given IV as a bolus in 
combination with glucocorticoids for additional immunosuppression in the initial acute 
management of IMHA or in an attempt to lower the necessary glucocorticoid dosage earlier 
92
. 
 
6.1.4 Cyclosporine A 
The use of cyclosporine A for immune mediated disease has been reported in human as well 
as in veterinary medicine
3
. The drug has a selective T-cell immunosuppressive activity that 
inhibits phosphatase activity of calcineurin, thereby preventing the transcription of many 
cytokines and particularly IL-2, which is necessary for proliferation and maturation of T- 
cells
94
. Activated T cells are the most susceptible to its effects. Antibody formation against T-
cell-dependent antigens is thus reduced
3
. In humans it is used primarily to prevent transplant 
rejection and is very useful for the treatment of chronic inflammatory skin conditions, and its 
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efficacy for these pathologies has been demonstrated in dogs too
94
.The original vegetable oil 
formulation was found to have poor and unpredictable oral bioavailability, but the current 
micro-emulsified formulations (cyclosporine modified or micro-emulsified) have markedly 
improved bioavaliability and attain more consistent and predictable therapeutic blood levels
75
. 
Interestingly, the concurrent use of ketoconazole to inhibit cyclosporine metabolism has been 
shown to reduce the required dose and hence the cost of cyclosporine therapy
95
. Several 
studies have found that this drug combination resulted in financial savings of 40% to 70% 
compared to the use of cyclosporine alone 
75
. Another recent study found cyclosporine in 
combination with prednisone to be less effective then azathioprine in combination with 
prednisone 
96
. The authors estimated that since cyclosporine has a low availability (35%) after 
oral dosing in healthy animals, it is to be expected that this absorption would be reduced in 
hypovolemic animals with constricted splanchnic vessels. It is thus possible that although 
cyclosporine may be an effective immunosuppressive agent, it may not be absorbed in 
sufficient concentrations to control the immune response in collapsed animals, including those 
with IMHA
96
. Further studies regarding the pharmacokinetics of the drug in hypovolemic 
dogs are warranted. 
Unlike cyclophosphamide and azathioprine, cyclosporine is not myelosuppressive and is 
suitable for use in patients with non-regenerative forms of IMHA 
75
. Adverse effects of 
cyclosporine in dogs include vomiting, diarrhea, anorexia, gingival hyperplasia, weight loss, 
alopecia, hypertension, and papillomatosis. Some more severe neoplastic side-effects such as 
lymphoma and squamous cell carcinoma are sporadically reported in dogs
3,97
, and are well 
known in cats 
98
 and in humans
99
. In dogs, given the commonly used oral dose of 5 mg/kg per 
day there have been few adverse reactions- mostly limited to vomit and diarrhea
96
, but some 
clinicians report that the immunosuppressive starting dose of oral microemulsified 
cyclosporine is 10 mg/kg q12–24h75.  
 
6.1.5 Mycophenolate mofetil 
Mycophenolate mofetil (MMF) was developed as an alternative to azathioprine with reduced 
myelotoxicity and hepatotoxicity and is now widely used in multi-drug regimes for prevention 
of human renal allograft rejection and for treating several human immune-mediated diseases 
such as inflammatory myopathy 
100
, lupus nephritis 
101
 and even AIHA and IMT 
102
. MMF 
44 
 
has also exhibited antimicrobial activity against pathogens including hepatitis C and human 
immunodeficiency virus 
103
. 
The drug is metabolized in the plasma and the liver into mycophenolic acid (MPA), a 
reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), a key enzyme in de-
novo purine biosynthesis. T- and B-lymphocytes are more dependent on this pathway than 
other cell types. Moreover, MPA is a fivefold more potent inhibitor of the type II isoform of 
IMPDH, which is expressed in activated lymphocytes, than of the type I isoform of IMPDH, 
which is expressed in most cell types. MPA has therefore a more potent cytostatic effect on 
lymphocytes than on other cell types. This is the principal mechanism by which MPA exerts 
immunosuppressive effects. 
Three other mechanisms may also contribute to the efficacy of MPA in immune response 
modulation. First, MPA can induce apoptosis of activated T-lymphocytes, which may 
eliminate clones of cells responding to antigenic stimulation. Second, by depleting guanosine 
nucleotides, MPA suppresses glycosylation and the expression of some adhesion molecules, 
thereby decreasing the recruitment of lymphocytes and monocytes into sites of inflammation 
and graft rejection. Third, by depleting guanosine nucleotides MPA also depletes 
tetrahydrobiopterin, a co-factor for the inducible form of nitric oxide synthase (iNOS). MPA 
therefore suppresses the production by iNOS of NO, and consequent tissue damage mediated 
by peroxynitrite. Additionally, the drug also suppresses primary, but not secondary, antibody 
responses by inhibiting differentiation, maturation and allostimulatory function of human 
monocyte-derived dendritic cells
103–105
 . 
Clinical use in the dog has emerged from extensive use in canine renal and bone marrow 
transplantation models. Significant potential advantages of MMF as an immunosuppressive 
agent in the dog include availability of a parenteral preparation, rapid onset of IMPDH 
inhibition (and hence immunosuppression) occurring 2 to 4 hours after dosing and low 
toxicity with signs primarily limited to gastrointestinal effects, although mild suspected 
allergic reactions have been reported with the parenteral preparation 
33
. Veterinary clinical 
usage of MMF for treatment of refractory immune-mediated disease is now quite widespread, 
especially for acquired myasthenia gravis 
106
 , IMHA and pemphigus vulgaris. One study 
performed on 30 cases of canine IMHA found no difference in short-term outcome for dogs 
with idiopathic IMHA between those treated with glucocorticoids and MMF or 
glucocorticoids and another adjunctive immunosuppressive agent. This was despite MMF 
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dogs presenting with clinicopathological data shown to be associated with a poorer prognosis. 
More importantly MMF administration was only associated with transient diarrhea in a small 
number of dogs
74
. This is an encouraging fact considering the wide spectrum of adverse 
affects other cytotoxic drugs cause. Nonetheless, the latter study had a few limitations 
regarding the uniformity of treatment protocols and further research is needed to establish the 
efficacy of MMF in comparison to other cytotoxic drugs. The standard dosage for MMF is 1,3 
to 4 mg/kg/day
74
.  
6.1.6 Human intravenous immunoglobulin 
Human intravenous immunoglobulin (IVIG) has broad but incompletely understood immune-
modulatory effects in people and has multiple clinical indications supported by controlled 
studies. In dogs, in vitro evidence that IVIG competitively inhibits the binding of canine IgG 
to monocytes by saturation of Fc receptors provides rationale for use in IMHA and IMT by 
prevention of phagocytosis of antibody-coated erythrocytes and platelets 
107,108
. The authors 
of the latter study have also documented IVIG binding to canine T (CD4 and CD8) and B 
cells in vitro. Human data suggest that IVIG interferes with Fas (CD95) – Fas ligand 
(CD95R) induced apoptosis in lymphocyte-mediated cytotoxicity of target cells, providing a 
possible explanation for suggested efficacy in canine immune-mediated skin diseases such as 
erythema multiforme. Additional mechanisms of immunosuppression in people recently 
described by Ballow
109
 include:  
Saturation of the FcRn receptors to enhance the clearance of autoantibodies; inhibition of 
complement uptake on target tissues; inhibition of the differentiation and maturation of 
dendritic cells; restoration of the idiotypic–anti-idiotypic network; suppression or 
neutralization of cytokines by specific antibodies in the IVIG; blockage of binding of 
adhesion molecules on leukocytes to vascular endothelium; blockage of Fas ligand–mediated 
apoptosis by anti-Fas antibodies in the IVIG; induction of apoptosis with anti-Fas antibodies 
at high concentrations of IVIG; neutrophil apoptosis by anti–Siglec-9 antibodies in IVIG; 
Induction of inhibitory FcgRIIb receptors on effector macrophages; neutralization of growth 
factors for B cells such as B-cell activating factor and inhibition of T cell–proliferative 
responses; expansion and activation of a population of Treg cells
107,108,110–112
.  
Although IVIG has been used for various conditions in dogs, efficacy data are limited to case 
reports and two small controlled studies. In one study, a group receiving hIVIG tended to 
have stabilization of PCV approximately 1 day sooner than the placebo group, yet this 
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difference was not significant. Survival to discharge was comparable between the dogs 
receiving hIVIG and placebo. The authors therefore concluded that the therapeutic benefit of 
hIVIG is not enough to warrant the additional costs of the treatment 
55
.While this situation 
persists, use of IVIG may be difficult to justify on ethical (and financial) grounds at times 
when demand is high for human patient
33
.  
IVIG has recently been shown to promote hypercoagulability and an inflammatory state in 
healthy dogs in a small controlled trial 
113
, but not in IMHA
55
 or IMT dogs 
114
 (although the 
latter report only included 5 dogs). This would question the application of this treatment to 
dogs with IMHA in which a hypercoagulable state is already recognised
33
.  
The protocol frequently used by some clinicians is the following: 0.5 g/kg daily reconstituted 
with sterile water, for 3 consecutive days. Infused hIVIG must be refrigerated and 
administered within 24 hours of reconstitution to minimize risk of bacterial contamination
55
.  
 
6.1.7 Danazol  
Danazol is a synthetic androgen which is reported to down-regulate macrophage Fc receptor 
expression, reduce antibody binding to erythrocytes, stabilize erythrocyte membranes and 
alter T cell homeostasis. It has been used as an adjunctive agent with glucocorticoids in 
canine IMHA and IMTP, but its efficacy is only supported by a few published case-studies 
115,116
 and its usage is now uncommon. Danazol can be hepatotoxic in dogs
33
. 
 
6.1.8 Leflunomide 
 Leflunomide is an isoxazole immune-modulatory drug, licensed in some countries for 
treatment of human rheumatoid arthritis. The primary metabolite reversibly inhibits dihydro-
orotate dehydrogenase, the rate-limiting enzyme in de novo pyrimidine synthesis. At high 
concentrations, cytokine and growth factor receptor-associated tyrosine kinase activity are 
inhibited 
117
. T and B cell proliferation is inhibited and the drug has significant anti-
inflammatory effects. Work in rodent models of contact allergy and inflammatory brain 
disease also suggests that leflunomide may induce regulatory T cells and that induction of 
CD86 expression and IL-10 production by microglial cells could play a role in the CNS 
effects. Leflunomide was first used in dogs as an adjunctive agent in renal transplantation but 
has been applied to treatment of a range of immune-mediated and inflammatory diseases. It is 
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used primarily in cases refractory to conventional medications or where glucocorticoid use is 
contraindicated – like in one case of diabetic miniature schnauzer that was diagnosed with 
Evans’ syndrome and treated successfully with leflunomide and hIVIG118. Despite having a 
long elimination half-life and potential hepatotoxicity and myelotoxiticty, these effects seem 
rare. Some controlled studies have been performed in the dog, mainly revolving the use in 
renal transplantation
119
 and polyarthritis 
120
, some presenting promising results
33,75
.  
 
6.1.9 Splenectomy 
The spleen has a central role in the pathogenesis of IMHA. The spleen is typically the major 
site of mononuclear phagocytic system removal of IgG- coated RBCs in patients with IMHA 
and has an integral role in antigen presentation and autoantibody production. Removal of the 
spleen can eliminate a major contributor to the pathogenesis of RBC destruction in patients 
with IMHA but is reserved for patients that do not respond to standard immunosuppressive 
therapy or that experience adverse effects associated with drug therapy
69
. A recent 
preliminary study in a relatively small group of dogs described the use of early splenectomy 
to treat patients with acute IMHA and found that dogs treated with glucocorticoids and 
azathioprine as well as splenectomy within 48 hours of presentation had shorter recovery 
times and higher survival rates than dogs treated with glucocorticoids and azathioprine alone. 
Based on these preliminary results, further investigation into early splenectomy is warranted. 
Risks associated with splenectomy include complications associated with anesthesia and 
surgery and an increased predisposition to infectious diseases (bacterial sepsis, blood-borne 
parasitemia) that would normally be controlled by the spleen
75
. 
 
6.1.10 Plasmapheresis 
Plasmapheresis (PP), or the removal of plasma and its constituents from whole blood, can be 
acutely effective in decreasing the antibody and immune complex concentrations within the 
blood. A wide variety of immune mediated diseases have been treated using plasmapheresis 
with mixed results. In humans, immune-mediated thrombocytopenia (IMT), immune-
mediated hemolytic anemia (IMHA), SLE, myasthenia gravis, rheumatoid arthritis, 
glomerulonephritis have all been treated successfully with plasmapheresis. Dogs with SLE, 
monoclonal gammopathy and myasthenia gravis have also been treated successfully with this 
modality
121–124
. The clinical effectiveness of PP in the treatment of autoimmune disease may 
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be due to partial removal of autoantibodies, immune complexes, complement components, 
pro-inflammatory agents, and soluble adhesion molecules
94
. Plasmapheresis may be used as 
an emergency procedure before cytotoxic therapy has had time to take effect. Temporary 
stabilization of acute hemolysis occurred in response to plasmapheresis in two IMHA dogs 
but was suspected to have contributed to the death of one of them
121
. Another case study 
reported a complete resolution of anemia with minimal complications following a plasma 
exchange with membrane separation PP technique and fresh-frozen plasma
125
. The author 
therefore concluded that since transfusion requirements appeared to be reduced, and the 
procedure was well tolerated, there may be a place for this modality in severe cases to act as a 
bridge until medical therapy takes full effect. Because of the cost of performing this therapy, 
and the potential requirement for multiple treatments, it should be reserved for selected 
patients
3,125
. PP as a therapeutic approach is yet controversial since the main location of 
hemolysis in IMHA is extra-vascular, and the vast majority of auto-antibodies are adhesive to 
the cellular component and therefore further study is required. 
 
 
6.2 Supportive therapy 
Supportive care for IMHA dogs is directed at two primary goals: to reduce organ damage 
caused by hypoxia and to prevent the formation of life threatening thromboemboli. 
Complimentary treatment such as antibiotic coverage, gastro-protectors, antioxidants, 
electrolyte imbalance correction and fluid-therapy are highly suggested as well.  
In severely anemic dogs (PCV < 15%), supportive therapy in the form of cross - matched 
whole blood or packed RBC transfusion may be required. The benefits of transfusion in 
providing short - term oxygen carrying capacity outweigh any possibility of enhancing 
hemolysis by providing greater antigenic load 
6
. The consequences of severe anemia include 
tissue hypoxia, acid-base disturbances and hypotension. Blood transfusion addresses many of 
these problems by improving oxygen carrying capacity and intravascular volume; supporting 
blood colloidal pressure; and improving tissue perfusion. Importantly, blood replacement 
normalizes the body’s buffering capacity, which is crucial in states of lactic acidosis and 
mixed acid-base disturbances and is frequently depleted in states of severe anemia 
126
.The 
decision to administer a blood transfusion to a patient with IMHA should be based on the 
presence of anemia-related clinical signs, such as tachypnea, tachycardia, and weakness
75
, as 
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well as the velocity of Hct decline. Several studies demonstrated a relationship between 
reduced short-term survival and transfusion, but this is partially due to the fact that dogs that 
receive blood transfusion are more anemic
2,20
. The possible correlation between 
hypercoagulability or PTE and PRBC transfusion is yet to be determined. 
6.2.1 Thromboprophylaxis in IMHA 
Unfractionated heparin, ultra low doses of aspirin (ULDA), and clopidogrel have been used as 
thromboprophylactic agents in dogs with IMHA. Given that venous thrombi and PTE are 
common death cause, fibrin rich thrombi have been documented, and TF-induced activation 
of coagulation likely initiates thrombus formation in hemolysis, the use of drugs that target 
coagulation is a logical choice for dogs with IMHA. Preferences for the use of one or another 
combination of these therapies in treatment of IMHA vary among clinicians and are based on 
personal experience, method of administration, cost and monitoring requirements. 
Heparin  
Heparin is the standard of care for prevention of deep vein thrombosis and PTE. 
Unfractionated heparin (UFH) facilitates the AT-mediated inactivation of thrombin and factor 
Xa. Factors IXa, XIa, VIIa, and XIIa are also inactivated by this complex. Heparin also 
facilitates release of tissue factor plasminogen inhibitor from endothelial cells and inhibits the 
binding of phosphatydilserin to thrombospondin which reduces the protrombinase and tenase 
complex formation. Clinically relevant doses of heparin inhibit this binding in a 
concentration- dependent manner. Additionally, it inhibits complement. Complement 
inhibition is thought to contribute to the anti-thrombotic effects of heparin in women with 
APLA syndrome. Heparin inhibits hemolysis-induced thrombin generation in vitro. Thus, 
heparin appears to target many of the pathways that might contribute to the prothrombotic 
state in IMHA
52,54
. Importantly, UFH therapy requires diligent and appropriate monitoring for 
each individual patient since standardized dosing results in highly variable levels of 
anticoagulation in different patients. In fact, some previous studies suggest UFH is not 
effective in preventing thromboembolism in IMHA; however, it has been hypothesized that 
sub-therapeutic dosing could explain the seeming lack of efficacy 
127
. The same study 
suggests that individually adjusted UFH therapy using anti-Xa monitoring reduced case 
fatality rate in dogs with IMHA when compared with dogs receiving fixed low dose UFH 
therapy
127
. Measuring anti-factor Xa activity in individual patients is the gold standard for 
determining whether therapeutic UFH heparin levels are reached in human medicine
52
. Even 
51 
 
so, the range of anti-factor Xa activity needed to prevent thrombosis in dogs with IMHA has 
not been established. A prospective controlled clinical trial by Helmond et al. showed that 
doses ranging from 150U/kg to 566U/kg QID were necessary to achieve target anti-factor Xa 
activity of 0.35–0.7 U/mL in individual dogs 127. APTT was suggested as a correlated 
indicator to anti-factor Xa activity, and is more available for clinicians to perform. However, 
predicting whether plasma anti-factor Xa activity is within a target range based on 
prolongation of APTT in individual normal dogs is difficult. Furthermore, the relationship 
between APTT and heparin activity in normal dogs depends on the reagent used in the APTT 
assay. In diseased patients, APTT can be affected by many additional factors: 
hyperfibrinogenemia, hyperbilirubinemia and corticosteroid treatment are only some of them. 
Monitoring heparin therapy is also important due to the risk of bleeding associated with its 
use. However, it appears that the risk of bleeding associated with UFH therapy in dogs with 
IMHA might be less than in normal dogs
52
,  this may be due to reduced bioavailability caused 
by the presence of inflammatory mediators found in the blood of IMHA dogs
127
.  
Low-molecular-weight heparin (LMWH) has been suggested as an alternative to UFH in dogs 
because of more predictable pharmacokinetics and similar efficacy and safety as compared to 
individually adjusted UFH therapy in people with deep vein thrombosis and other thrombotic 
disease. This translates to a reduced need for monitoring anti-factor Xa in most human 
patients, although monitoring is still recommended for critically ill patients. APTT is not used 
to monitor LMWH because the smaller heparin molecules are not large enough to inhibit 
thrombin while complexed to AT. In healthy dogs, enoxaparin administered at a dosage of 0.8 
mg/kg subcutaneously (SC) every 6 hours maintained target anti-Xa activity without 
hemorrhagic complications
128
 but data describing the use of LMHW in IMHA is limited
129
. 
Unfortunately, a recent study had failed to determine whether enoxaparin therapy can reduce 
mortality and thrombotic complications in dogs with primary IMHA compared with other 
anticoagulation protocols 
130
. 
  
Platlet inhibitors: Aspirin and Clopidogrel 
Ease of use and lack of need for intensive monitoring make platelet inhibitors, such as aspirin 
and clopidogrel, attractive thromboprophylactic agents for dogs with IMHA. Aspirin is a 
cycloxygenase inhibitor. Thromboxane A2 is produced by platelets in a COX-1 dependent 
manner. Thromboxane A2 is a potent platelet agonist. Ultra low doses of aspirin (ULDA) 
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inhibit platelet thromboxane A2 production while preserving COX-1 dependent prostacyclin 
(which is antithrombotic) production from endothelial cells. The dose of aspirin needed to 
achieve this effect in normal dogs or dogs with IMHA has not been established. The dose of 
0.5 milligrams of aspirin per kilogram per day has been shown to inhibit normal canine 
platelet aggregation in vitro when Adenosine diphosphate (ADP) and collagen are used as 
agonists. Nevertheless, up to 30% of dogs did not exhibit an anti-platelet effect depending on 
the parameter measured, suggesting that the dose may be inadequate to inhibit platelet 
function in some individuals. Another study showed that dosing every 12 hours was more 
effective at inhibiting platelet aggregation than administering aspirin every 24 hours in normal 
dogs using this dose. This dose does not increase the risk of gastrointestinal ulceration in 
normal dogs treated with immunosuppressive doses of prednisone. Whether concurrent use of 
prednisone and aspirin in dogs with IMHA increases the risk of gastrointestinal ulceration has 
not been determined, however anecdotally it does not appear to be common 
20,52,131
.  
Clopidogrel has been shown to inhibit platelet aggregation in dogs. The drug irreversibly 
inhibits the platelet ADP receptor. ADP is a potent activator of platelets. A recent prospective 
study showed that dogs with IMHA treated with clopidogrel had comparable short-term 
survival to dogs treated with ULDA (0.5mg/kg/day) or clopidogrel combined with ULDA. 
The overall mortality rate at 90 days for this study was 21%, and thrombotic events were 
suspected or confirmed in 3/5 fatalities. Therefore, clopidogrel may represent a safe and 
equally effective alternative means of anticoagulation in dogs unable to tolerate aspirin 
therapy
132
. 
 
Whether UFH is a superior thromboprophylactic agent to ultralow-dose aspirin or clopidogrel 
for canine IMHA is not clear, and authors have presented contradicting results 
20,127,133
. It 
seems like future research should focus on understanding the pathophysiology of thrombosis 
in IMHA and provided solutions that will confront specific mechanisms of hypercoagulation. 
Microparticles expressing Phosphatydilserin and Tissue-factor might be used as markers for 
thrombotic risk as well as the target of future treatment
54
. For instance, a platelet GPIIb-IIIa 
receptor antagonist (abciximab), an anti-platelet drug used after percutaneous coronary 
intervention in humans has been associated with the reduction in microparticle release by 
platelets at high shear stress. In addition to integrin antagonists, statins are another class of 
52 
 
drugs already reported to reduce circulating microparticles levels. Statins also reduced 
endothelial microparticle release in TNF-alpha stimulated cells in culture
134
.  
Other future prospective currently research for human application are Biomimetic 
Nanoparticles. The selective depletion of disease-causing antibodies using nanoparticles 
offers a new model in the management of type II immune hypersensitivity reactions. The 
demonstration of pathophysiologically inspired nano engineering serves as a valuable 
prototype for additional therapeutic improvements with the goal of minimizing therapy-
related adverse effects. Through the use of cell membrane-cloaked nanoparticles, nanoscale 
decoys with strong affinity to pathological antibodies can be administered to disrupt disease 
processes in a minimally toxic manner. These biomimetic nanoparticles enable indiscriminate 
absorption of pathological antibodies regardless of their epitope specificities. Through both in 
vitro and in vivo studies on rodent models, Copp et al. demonstrated efficacy of RBC 
membrane-cloaked nanoparticles to bind and neutralize anti-RBC polyclonal IgG effectively, 
and thus preserve circulating RBCs 
135
. 
 
In conclusion the quality of evidence available to guide clinical decisions in the treatment of 
IMHA is generally poor and many times ambiguous. Further research of a higher quality will 
be required to investigate existing and novel therapeutic regimens for the disease. The low 
incidence of the disease also emphasizes the importance of multi-center cooperation to 
maximize the enrollment of suitable cases, the need to apply robust and consistent enrollment 
criteria and report consistent treatment protocols, which take account of long-term treatment, 
tapering, and responses to relapses 
73
.  
 
 
 
Chapter seven: Experimental part 
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7.1 Introduction 
Immune-mediated hemolytic anemia (IMHA) is the most common severe anemia of dogs and 
is less frequent in cats
5
. The majority of cases are currently considered to be primary IMHA
6
.  
It is also reported to be the most common immune-mediated disease of dogs 
4
. Auto-immune 
diseases represent some of the most frustrating types of disorders that are diagnosed and 
treated in veterinary medicine. Given the nature of these diseases, in which an abnormal 
immune response against the body's own cells occurs, treatment is difficult and necessarily 
includes suppression of immune defenses
3
.     
 Primary IMHA (pIMHA) is a severe disease with high mortality rates, mainly in the first two 
weeks that follow its presentation
4
. Due to its complex pathophysiology and the numerous 
components that take part in the pathological mechanisms that cause the disease, pIMHA has 
been the subject of numerous studies, in veterinary and human medicine alike.  
The following chapter is a retrospective study of fifty-two cases of canine primary immune 
mediated hemolytic anemia from two veterinary teaching hospitals in two different countries; 
Italy and Israel. The goals of this study were to analyze the clinical and clinicopathological 
alterations of this complex disease and to compare them between the two hospitals and the 
corresponding findings described in veterinary scientific literature. 
 
7.2 Materials and Methods 
7.2.1 Materials 
Cases of primary IMHA were collected from two veterinary teaching hospitals; "Mario 
Modenato Veterinary Teaching Hospital" of the Department of Veterinary Sciences, Pisa 
University, Italy and the Veterinary Teaching Hospital of the Koret School of Veterinary 
Medicine, Hebrew University of Jerusalem, Israel. For simplification they will be further 
referred as Pisa and Beit-Dagan respectively. The search for cases was considerably easier at 
the Pisa facility since an electronic database is used by the clinicians to store all patient data. 
To retrieve cases from the database it was enough to search for a certain hematocrit cut-off, 
typical erythrocyte deformation and the test for anti-RBC antibody presence on erythrocyte 
surface in the computerized data-base. At Beit-Dagan data collection was more complicated 
since there is currently no electronic database system used to store patient data, therefore the 
data collection was based on searching for discharge letters that contained the words 
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hemolytic anemia or the abbreviation IMHA. This system of data collection presents a major 
bias risk since the owners of the patients who died during hospitalization did not receive a 
discharge letter. For this reason, another search was performed using the laboratory paper 
archive for low hematocrit, presence of spherocytes or suspect of IMHA as a motive for the 
exam request. The chart numbers of possible cases were collected and the corresponding 
clinical charts were then retrieved from the archive present in the hospital. The search in both 
hospitals yielded 106 potential cases that responded to the inclusion criteria, 54 of which were 
then excluded from the study for meeting the exclusion criteria as well (see the next section).  
 
7.2.2 Selection of cases 
Study inclusion criteria included Hct ≤ 30% associated with either positive or weak positive 
result of IgG and IgM antibodies on erythrocytes detected by flow-cytometry, or positive 
osmotic fragility test, or evidence of spherocytosis or auto-agglutination in blood smear. 
Clinical records were excluded (n = 54) if an underlying disease process was identified or if 
results were positive for polymerase chain reaction (PCR) or serologic tests for Ehrlichia 
spp., Borrelia spp., Leptospira spp., Leishmania spp. or Rickettsia spp. or if a neoplastic 
process was identified.  
The main causes for exclusion varied greatly between the two hospitals. The main cause for 
exclusion in Beit-Dagan was the identification of Ehrlichia spp. as a primary cause for 
anemia, using a PCR technique. Babesia spp. was likewise present as a primary cause of 
IMHA, but with a minor incidence. At the Pisa hospital the frequency of exclusion for PCR 
or serologic positivity to tick borne disease was minor. The most common excluded cases 
were infected with either Leishmania spp. or Leptospira spp..  Ehrlichia spp. infection was 
reported as well, but less commonly. Sporadic cases of Babesia spp. and Rickettsia spp. 
seropositivity were reported. Other excluded cases from both hospitals were diagnosed with 
Heinz body anemia, leukemia and autoimmune conditions like Pure Red Cell Aplasia and 
immune mediated thrombocytopenia without RBC destruction. 
 
 
7.2.3 Methods 
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Data collected for each case included: Body weight at initial evaluation; age; gender; history 
taken by a clinician or a student; physical examination on arrival which included patient's 
body condition score, rectal temperature, heart rate, color of mucous membranes, evaluation 
of hydration level, sensorial state and all other clinical observations made by the clinician. 
Diagnostic workup included:  
(1)  Complete blood count (CBC) including a blood smear for microscopic evaluation 
Blood sample was collected in a potassium-ethylenediamine tetraacetic acid (EDTA) test tube 
and analyzed within 2 hours of collection. Complete blood count was performed using 
hematologic analyzers; IDEXX ProCyte Dx
 ®
 (laser flow cytometry, optical fluorescence, and 
Laminar Flow Impedance) at Pisa and Diatron Abacus
 ®
 or Arcus
 ®
 (volumetric impedance) at 
Beit-Dagan. The Analysis provided the following information: Red blood cells (RBC) 
10
6
/µL, hematocrit (Hct)%, hemoglobin (HGB) g/dL, mean corpuscular volume (MCV) fL, 
mean corpuscular hemoglobin (MCH) pG, mean corpuscular hemoglobin concentration 
(MCHC) g/dL, red blood cell distribution width  (RDW) %, platelet (PLT) 10
3
/µL, white 
blood cells (WBC)   103/ µL, absolute numbers (103/ µL) and percentage of neutrophils, 
lymphocytes, eosinophils, monocytes and basophils. When available, a manual differential 
count of leukocytes was considered to be more accurate than the automated count reported by 
the automated analyzer.       
 At Pisa the blood smear was stained in an automated slide stainer using a May-Grünwald-
Giemsa method. Evaluation included a differential leukocyte count, a leukocyte and 
erythrocyte morphological evaluation and a platelet morphological and quantitative 
assessment. The examination was performed by the experienced personnel of the clinical 
pathology laboratory. Morphologic examination of blood smear indicated alterations 
according to a scale of 1+ to 4 + or +/- based on frequency of alteration observed per 100 
WBC counted. 
At Beit-Dagan the blood smear was stained in an automated slide stainer using a modified 
Wright’s stain. Evaluation included morphological evaluation of erythrocytes and leukocytes 
and a morphologic and quantitative assessment of platelets. The blood smear examination was 
performed in the majority of cases by the clinician responsible for the case. Morphologic 
examination of blood smear indicated alterations using a brief description of the slide's RBC, 
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WBC and PLT populations, and were then translated to the same scoring system used in Pisa 
in the following manner ; slight ( -/+), mild (1+), moderate(2+), severe (3+), very severe (4+).    
 
(2) A broad biochemistry profile in serum or heparinized plasma; 
Samples were analyzed in an automated biochemistry analyzer (Liasys
®
 and Cobas integra 
400
®
 at Pisa and Beit-Dagan respectively). The profile included the following parameters: 
total plasmatic protein (TP) g/dL, albumin (ALB) g/dL, globuline  g/dL, Fructosamine 
mcmol/L (Pisa only), C-reactive protein mg/dL (Pisa only), total calcium mg/dL, phosphate 
mg/dL, iron mcg/dL (Pisa only), urea mg/dL, creatinine mg/dL, total bilirubine mg/dL, 
cholesterol mg/dL, triglyceride mg/dL, glycemia mg/dL, alkaline phosphatase (ALKP) U/L, 
gamma-glutamyl transpeptidase (GGT) U/L, aspartate transaminase (AST) U/L, alanine 
aminotransferase (ALT) U/L, creatine kinase (CK) U/L, lactate dehydrogenase (LDH) U/L, 
Amylase U/L, sodium (Na) mEq/L, potassium (K) mEq/L, chloride (Cl) mEq/L, Total CO2 
(TCO2) mEq/L (Pisa only). In this study only the following parameters were examined:  
 Total plasmatic protein (TP) g/dL 
 Albumin (ALB) g/dL 
 Total bilirubine mg/dL 
 C-reactive protein mg/dL (Pisa only) 
(3) Serology or PCR in order to diagnose infective agents as cause of IMHA: 
 Ehrlichia spp; using indirect immunofluorescence assay (IFA) in Pisa, seronegativity 
was established if the titer was lower than 1/40. PCR technique was used in Beit-
Dagan. 
 Babesia spp; using indirect immunofluorescence assay (IFA) in Pisa, seronegativity 
was established if the titer was lower than 1/64. PCR technique was used in Beit-
Dagan.  
 Leishmania spp; using a blood marrow/lymph node aspirate examination or an 
indirect immunofluorescence antibody test (IFA) with a positivity cut-off of 1/160 or 
RT-PCR technique in Pisa as well as in Beit-Dagan.  
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 Leptospira spp.; Determination of antibody titer by microscopic agglutination test 
(MAT). 
 Borrelia spp, Rickettsia spp; using indirect immunofluorescence assay (IFA) in Pisa 
with seronegativity established if the titer was lower than 1/80. 
 
 
 (4)  Flow cytometry for detection of IgG and IgM anti-RBC on the surface of RBCs; 
This assay was performed in twenty-two cases out of thirty cases in the Pisa group. Osmotic 
fragility test for detection of spherocytes in blood sample was performed in thirteen cases out 
of twenty-two cases in the Beit-Dagan group. In-slide saline auto agglutination test was 
performed in four cases.  
Out of fifty two cases of primary IMHA identified for this study, forty eight patients were 
presented during a first hemolytic crisis and four patients were in relapse after being formerly 
diagnosed and treated for the disease. Eight patients were in treatment with corticosteroids. 
 Anemia was classified based on MCV and MCHC values for each patient. Anemia was 
defined as microcytic, macrocytic or normocytic if the value of MCV was lower, higher or 
within reference ranges, respectively. Anemia was defined as hypochromic, hyperchromic or 
normochromic if the value of MCHC was lower, higher or within reference ranges, 
respectively. The definition "Hyper-chromic" is inaccurate since the erythrocyte cannot "over-
saturate" with hemoglobin. This error usually indicates biological or mechanical hemolysis or 
that the sample is lipemic. For reference ranges see APPENDIX. 
Statistics  
The entire study population was divided in two groups; the first group included all the 
patients with IMHA selected from the Pisa hospital and the second group included all the 
patients with IMHA selected from the Beit-Dagan hospital. The groups were then compared 
using statistical analysis for the various parameters regarding: age, gender, breed , season of 
clinical manifestation, clinical presentation and clinicopathological findings.  
A control population was selected from the Pisa hospital electronic database and will be 
referred to as control group. The control group includes all canine patients, treated between 
58 
 
May 1
st
, 2010 and January 31
st
 2016 at the Pisa hospital.  It was then used as comparative 
database to assess factors regarding gender and breed predisposition in the Pisa study group 
(patients ill with IMHA). Unfortunately, for lack of data, it was impossible to make the same 
analysis for the Beit-Dagan study group. 
The study population was divided into sub groups based on the season of clinical 
presentation. The division was made in consideration of climate differences between the two 
countries. The seasons were defined as: Winter – December to February, Spring- March to 
May, Summer- June to August in Pisa and June to September in Beit-Dagan, Fall-September 
to November in Pisa and October to November in Beit-Dagan. 
A large database was created using Microsoft Excel. Statistical analysis of data was 
performed under Windows platform using MEDCALC
 
software. For all continuous 
parameters, the normality of data distribution was evaluated by means of the D'agostino-
Pearson test. Normally and non-normally distributed continuous parameters are reported as 
mean ± standard deviation (SD) and as median and range (minimum observation – maximum 
observation), respectively. Study groups included; the Pisa group, the Beit-Dagan group and 
the Control group. Comparison between the different groups was made by means of the Chi-
squared test for normally distributed numeric parameters or Mann–Whitney test for non-
normally distributed numeric parameters. Proportions of categorical variables expressed as a 
percentage were compared using a Chi-squared test for independent samples. For all tests 
applied, P < 0.05 was considered statistically significant. Karl Pearson correlation test was 
used to evaluate correlations between variables. Correlation coefficient values |r =/> 0.3| were 
considered not significant, values between |0.3| and |0.5| were considered weakly correlated 
and values |r =/> 0.5| were considered moderately correlated. Correlations were considered 
significant if P was < 0.05.  
7.3 RESULTS 
7.3.1 SIGNALMENT 
AGE 
In this study the age of first clinical presentation was taken in account in all cases, including 
cases that were presented to the hospitals during a relapse of the disease (n=4), using the 
documented history of each patient. The group was divided in four age categories and the 
mean and standard deviation calculated for each hospital and for the entire study group. Age 
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was normally distributed in both groups. Although minimal differences were visibly notable 
between groups they were not statistically significant (P >0.05) using a Chi-squared test.  
Table 7.1 Age groups and descriptive statistics of age.  
Age of first clinical manifestation 
(years): Total Beit Dagan Pisa 
0-1 1 1 0 
2-4 13 7 6 
5-7 13 5 8 
8+ 25 9 16 
Mean ± SD 7.00±3.36 6.25± 3.47 7.53± 3.24 
Variance 11.3 12.1 10.5 
Nº dogs 52 22 30 
 
GENDER 
The entire study population was composed of 29% females (n=15), 38% neutered females 
(n=20), 23% males (n=12) and 10% castrated males (n=10). 
There were no significant differences in gender representation between the two groups using 
the Chi-squared test (P >0.05).  
Table 7.2 Gender distribution. F; female, FN; neutered female, M; male, MC; castrated male. 
Gender Pisa Beit Dagan Total population 
F 10 5 10 
FN 9 11 9 
M 8 4 8 
MC 3 2 3 
total 30 22 30 
 
 
 
 
 
 
 
 
 
 
 
 
Chart 7.1 Gender distribution of the entire study group. 
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A comparison was made between the control group gender distribution and the Pisa group 
gender distribution. Neutered females were overrepresented in the Pisa study group when 
compared to the control group using a chi squared test for comparison of proportions for 
independent samples (P= 0.021). We didn't find any other significant differences regarding 
gender between the two groups. 
 
 
 
Table 7.3 Gender distribution of control group and Pisa study group in terms of absolute numbers and 
percentiles.  
Sex 
Control 
group % 
Pisa study 
group % P= 
F 7806 40 10 33 > 0.05 
FN 2709 14 9 30 0.021 
M 7831 40 8 27 > 0.05 
MC 1301 6 3 10 > 0.05 
Total 19647 
 
30 
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Chart 7.2 Gender distribution in Pisa study group compared to the gender distribution of the control 
group. 
 
 
 
BREED 
Both the Italian and the Israeli groups had a high prevalence of mixed breed patients and 54% 
of the study population is composed of mongrel dogs (n=25). There were no significant 
differences between Pisa and Beit-Dagan groups regarding breed (P>0.05) using a Chi-
squared test. Labrador Retriever and Cocker Spaniel breeds were overrepresented in the entire 
study population, which included 4 patients of each of these breeds. Nonetheless, when we 
compared the Pisa study group to the control population, no significant difference was noted 
between the two groups regarding the Labrador breed, since it is overrepresented in the entire 
hospital population as well (P >0.05). On the contrary, Cocker Spaniels were overrepresented 
in the Pisa study group in comparison to the control population (P=0.025). Another breed, 
Maltese, was likewise more frequent in the study group when compared to the hospital 
population (P=0.012).     
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Table 7.4: Breed representation among study groups. 
Breed Pisa Beit-Dagan Total 
mongrel 13 12 25 
Cocker Spaniel 3 1 4 
Labrador 2 2 4 
Maltese 2 0 2 
Miniature Poodle 2 1 3 
Lagotto Romagnolo 1 0 1 
American 
Staffordshire 1 0 1 
Pug 1 0 1 
Bernese 1 0 1 
Springer Spaniel 1 0 1 
Setter 1 0 1 
Boxer 1 0 1 
Breton 1 0 1 
Collie 0 1 1 
Australian Shepherd 0 1 1 
German Shepherd 0 1 1 
Sharpei 0 1 1 
Japanese Spitz 0 1 1 
Shih-tzu 0 1 1 
 
 
SEASON 
 
Following the division of the study populations into sub-groups based on season of clinical 
presentation of the disease, a Chi-squared test was performed separately for each season to 
look for significant difference in seasonal occurrence between the two hospitals. No 
significant differences were found (P >0.05). Another Chi-squared test was performed in 
order to evaluate if significant differences exists in the occurrence of the disease between the 
different seasons. The test showed no increased occurrence in any of the seasons (P >0 .05).   
Table 7.5 Season of clinical presentation.  
Season Pisa 
Beit-
Dagan Total 
Spring 11 4 15 
Summer 9 7 16 
Fall 6 3 9 
Winter 4 8 12 
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Chart 7.3 Seasonal distribution. 
  
 
 
7.3.2 CLINICAL FINDINGS 
Clinical alterations reported in this study include alterations detected by owner- or better yet, 
symptoms, as well as clinical signs observed by clinician during the physical examination. 
Among dogs in this study group, the most common alterations detected by owners were 
lethargy reported in 88% of dogs (n=46), anorexia in 65% of dogs (n=34) and pigmenturia in 
35% of dogs (n=18). Most common clinical signs revealed by clinicians were pale mucous 
membranes reported in 88% of dogs (n= 46), tachycardia in 42% of dogs (n=22) and 
tachypnea in 38% of dogs (n=20). A Chi-squared test for proportions was used and some 
differences were noted regarding the clinical alterations between the two hospitals. They are 
reported in the table 7.6.  
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Table 7.6 difference in symptoms and clinical signs between the two hospitals. 
Symptom 
Pisa (n 
patients) 
Beit-Dagan (n 
patients) 
 
P= Total 
Pale mucous 
membrane 26 20 > 0.05 46 
Lethargy 25 21 > 0.05 46 
Anorexia 16 18 > 0.05 34 
Fever 12 7 > 0.05 19 
Cardiac murmur 12 6 > 0.05 18 
Pigmenturia 9 9 > 0.05 18 
Tachycardia 8 14 0.017 22 
Vomit 7 6 > 0.05 13 
Icterus 6 11 0.048 17 
Tachypnea 5 15 0.001 20 
Lymphadenomegaly 4 4 > 0.05 8 
Syncope 4 1 > 0.05 5 
Cranial 
organomegaly 2 4 > 0.05 6 
Diarrhea 2 3 > 0.05 5 
 
Minor variation in the clinical presentation of the disease exists between the two groups. 
Symptoms which varied significantly were: increased respiratory rate and heart rate (P=0.001 
and P=0.017, respectively). Another parameter that differed significantly was icterus 
(P=0.048), which is a qualitative measurement that will be confirmed by comparing the total 
bilirubin value discussed in the biochemistry section (7.3.3). Arithmetic means and standard 
deviation of body temperature were similar between the two hospitals (38.8±0.815 and 
38.6±0.731 in Pisa and Beit-Dagan respectively) and a Chi-squared test performed on the 
data showed no significant difference (P>0.05) between the two hospitals.  
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Chart 7.4 clinical signs and symptoms for entire study group. 
 
  Correlation analysis preformed using the Karl-Pearson correlation coefficient found a 
moderate correlation between few symptoms: Icterus and pigmenturia (r =0.508, P= 0.001). 
Tachycardia and tachypnea were moderately correlated as well (r = 0.557, P= 0.0001).  
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7.3.3 CLINICOPATHOLOGICAL ALTERATIONS 
ERYTHROCYTES 
 
Table 7.7 comparison of erythrocyte parameters between the two hospitals. 
Parameter Pisa 
Range 
(min- 
max) median 
Beit-
Dagan 
Range 
(min-
max) Median P= 
RBC M\ųL n=30 0.93-5.48 2.00 n=21 
0.57- 
4.18 2.0 >0.05 
Hct % n=30 8.7-30.1 17.2 n=22 
4.8 - 
31.6 15.3 >0.05 
HGB g\dL n=30 2.2-12.5 4.7 n=21 2.1 -10.8 5.0 >0.05 
MCV fL n=30 
61.8-
110.9 81.3 n=21 
61.8 – 
84.0 75.5 0.004 
MCH pG n=30 19.3-29.4 24.4 n=21 
19.1-
61.7 25.8 >0.05 
MCHC g\dL n=30 22.5-36.0 30.3 n=21 
24.2-
73.2 34.0 0.001 
RDW % n=30 14.1-38.7 21.4 n=21 
10.0-
42.0 18.6 0.018 
 
Mann-Whitney tests were used for comparison of data for all parameters showed in table 7.7. 
Three erythrocyte indexes were significantly different between the two hospitals: Mean 
corpuscular volume (P=0.004), mean corpuscular hemoglobin concentration (P=0.001) and 
red blood cell distribution width (P=0.018). Reviewing the data we noticed that one dog from 
the Pisa group had significantly higher MCV (110.9) that could alter the calculation. 
Nonetheless, repetition of the statistic test after disregarding the extreme value yield similar 
results (P= 0.014). It appears that the Pisa group had indeed significantly larger erythrocytes 
in comparison with the Beit-Dagan group.  
Erythrograms of dogs with immune mediated hemolytic anemia are usually characterized by a 
highly regenerative, macrocytic, hypochromic anemia. In our study 67% (35/52) of dogs 
suffered from severe anemia defined by a hematocrit value equal or lower then 20. 33% 
(17/52) of dogs had moderate anemia at time of blood sampling, with hematocrit values of 
less than 30%. Classification of anemia was performed for all patients. 
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Table 7.8 Anemia classification comparison between hospitals. 
Type of anemia Pisa Beit-Dagan P= 
macrocytic-hypochromic 19 3 0.001 
macrocytic-normochromic 7 7 >0.05 
nomocytic-normochromic 3 2 >0.05 
normocytic-hypochromic 1 1 >0.05 
normocytic-hyperchromic 0 2 >0.05 
macrocytic-hyperchromic 0 6 0.005 
 
As seen in table 7.8, nineteen out of thirty patients in the Pisa group had macrocytic-
hypochromic anemia. The Beit-Dagan group was more variable in terms of anemia 
classification and had two types of anemia represented more frequently; macrocytic-
normochromic (7/21) and macrocytic-hyperchromic (6/21). Significant differences between 
groups were calculated using a Chi-squared test for proportions. We found significant 
difference in the proportions of the following types of anemia: macrocytic-hyperchromic 
(P=0.001) and macrocytic-hyperchromic (P=0.005).   
Table 7.9 Summery of entire study group anemia classification. 
Type of 
anemia normochromic hypochromic "hyperchromic"/hemoglobinemia 
normocytic 5 2 2 
microcytic 0 0 0 
macrocytic 14 22 6 
 
 Out of fifty-two dogs with IMHA in this study, 43% (22/51) had macrocytic-hypochromic 
anemia, 27% (14/51) had macrocytic-normochromic anemia, 12% (6/51) had macrocytic-
hyperchromic anemia, 10% (5/51) had normocytic-normochromic anemia, 4% (2/51) had 
normocytic-hypochromic anemia and 4%(2/51) had normocytic-hyperchromic anemia. RBC 
indexes of one dog weren't available. 
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Chart 7.5 Erythrocyte alterations reported on blood smear. NRBC; nucleated red blood cell. 
 
       
Blood smear evaluation was performed in fifty-one out of fifty-two patients. The most 
frequent erythrocyte morphological alteration in this study was polychromasia in 94% of dogs 
(48/51) followed by anisocytosis (42/51) and nucleated RBCs (42/51) in 82% of dogs. 
Spherocytosis (80%) and Howell-Jolly bodies (49%) were frequently observed as well (41/51 
and 25/51 dogs respectively). A few other morphological abnormalities were observed with a 
lower frequency and they were: microagglutination in 27% of dogs (14/51), hypochromia and 
poikilocytosis in 15% of dogs (8/51), schistocytes in 14% of dogs (7/51), microcytes, 
macrocytes, ghost-cells and target-cells in 6% of dogs (3/51), dacriocytes in 4% of dogs 
(2/51), cnizocytes and echinocytes in 2% of dogs (1/51).   
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Fig 7. 1 Nucleated red blood cell                                                            Fig 7.2 Anisocytosis. High arrow: microcyte, low arrow: spherocyte 
  
Fig 7.3.Howell-Jolly body                                                                                       Fig 7.4. Schistocyte 
  
All pictures were taken at the Veterinary Clinical Pathology Laboratory of the"Mario Modenato" Teaching Hospital, Dept. of Veterinary Sciences, Pisa 
University 
 
 
In this study 82% of dogs had NRBCs (42/51) in peripheral blood. The level of 
normoblastemia was divided in three categories based on number of NRBCs counted per 100 
WBC: 1-5, 6-10 and more than 11.  
Table 7.10 Degree of normoblastemia and its distribution in the study groups.  
NRBC: Pisa Beit Dagan Total P= 
>5 5 4 12 >0.05 
6 -10 8 6 11 >0.05 
>11 14 5 19 >0.05 
no 
normoblastemia 3 6 9 >0.05 
 
As seen in table 7.10, no significant differences regarding normoblastemia were found 
between hospitals, using the Chi- squared test.  
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Chart 7.6 Degree of normoblastemia. 
 
 
18% of dogs (9/51) had no normoblastemia, 24% (12/51) had five or less NRBCs in the blood 
smear, 22% (11/51) had between six to ten NRBCs in blood smear and 37% (19/51) had more 
than eleven NRBCs in blood smear. 
The presence of NRBCs was weakly but significantly correlated to the presence of 
macrothrombocytes (r=0.32, P=0.024), as well as to the presence of band neutrophils (r=0.32, 
P=0.024).   
LEUKOCYTES 
 
Table 7.11 comparison of leukocyte parameters between the two hospitals. 
Parameter 
(103/ųL) Pisa 
Range 
(min-
max) median 
Beit-
Dagan 
Range 
(min-
max) Median P= 
WBC  n=30 
7.7 - 
52.6 20.6 n=21 
3.6 - 
59.9 23.74 >0.05 
Neutrophils  n=30 
4.8- 
43.5 16.04 n=15 
2.82 - 
43.2 15.04 >0.05 
Band 
Neutrophils n=30 0 - 4.97 0.49 NA NA NA - 
Lymphocytes  n=30 0 - 4.1 1.00 n=19 
0.27 - 
14.80 3.93 0.001 
Monocyte  n=30 0 - 7.5 2.11 n=19 
0.29- 
5.49 1.17 >0.05 
Eosinophils n=30 0- 0.26 0.01 n=15 0 - 0.46 0.10 >0.05 
 
23% 
22% 
37% 
18% 
Degree of normoblastemia: NRBCs in 
peripheral blood 
5> 
6 -11 
11< 
no normoblastemia 
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Mann-Whitney tests were used for data comparison for all parameters specified in table 7.11. 
Significant difference was found in the lymphocyte count between the two hospitals 
(P=0.001). 
Chart 7.7 Leukocyte alterations. 
 
Leukocytosis was found in 80% (41/51) of dogs in this study, and was in 69% (35/51) of 
cases, neutrophilic. Band neutrophils were reported in 49% (25/51) of cases. Monocytosis 
was seen in 31% (16/51) of cases. Monocyte activation, Neutrophilic toxicity and lymphocyte 
reactivity were reported in 43% (22/51), 25% (13/51) and 20% (10/51) of cases, respectively. 
    
Fig 7.5. Activated monocyte (arrow), mature neutrophil.     Fig 7. 6. Band neutrophils 
 
All pictures were taken at the Veterinary Clinical Pathology Laboratory of the "Mario Modenato" Teaching hospital, Dept. of Veterinary Sciences, Pisa 
University. 
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PLATELETS 
 
Table 7.12 Platelet count.  
Parameter 
(103/ųL) Pisa 
range(min 
-max) median 
Beit-
Dagan 
range(min-
max) median P= 
PLT  
n= 
30 1 - 655 189 n=21 0 - 651 160 >0.05 
 
 
Platelets quantitative values in both hospitals were non parametric in distribution and 
therefore a Mann-Whitney test was used to compare these values. No significant difference 
was found regarding numbers of platelets between the two hospitals (P>0.05).  
The groups were then divided to three sub-groups based on number of platelets: dogs with 
platelet count lower then reference range (thrombocytopenia); dogs with platelet count within 
reference ranges; dogs with platelet count higher than the reference range (thrombocytosis). 
Absolute numbers of platelets were also verified by the blood smear assessment of platelet 
and the presence or absence of platelet aggregates.  
Table 7.13 Sub-groups of platelet quantities. 
Platelet count Pisa Beit-Dagan Total P= 
thrombocytopenia 10 8 18 >0.05 
In the reference 
range 18 10 28 >0.05 
thrombocytosis 2 3 5 >0.05 
 
Chart 7.8 Comparison of sub-groups between hospitals.  
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A Chi-squared test of proportions was used to compare sub-groups between the two hospitals. 
No significant differences were found between the two hospitals (p>0.05). 
55% (28/51) of dogs had a normal platelets, 35% (18/51) were thrombocytopenic and 10% 
(5/51) had thrombocytosis.  
Thrombocyte alterations were assessed in peripheral blood smear. 45% (23/51) of patients had 
lager then normal platelets (macro PLT) reported on blood smear. 2% (1/51) of patients had 
activated platelets reported on blood smear. Macrothrombocytes were not correlated with 
thrombocytopenia using a Pearson correlation test (r= -0.001, P=0.946) 
 
 Fig 7.7.Macrothrombocyte.. 
 
All pictures were taken at the Veterinary Clinical Pathology Laboratory of the "Mario Modenato" Teaching hospital, Dept. of  
Veterinary Sciences, Pisa University 
 
BIOCHEMISTRY PROFILE  
Table 7.14 Comparison of biochemistry parameters between the two hospitals. 
Parameter Pisa 
range 
(min-
max) Median 
Beit-
Dagan 
range 
(min-
max) Median P= 
TP n=28 4.9-8.7 7.00 n=21 3.9-7.7 6.30 0.02 
ALB n=28 2.0-4.5 3.19 n=21 1.7-4.4 3.10 >0.05 
Bilirubin n=28 0.19-9.2 0.80 n=19 
0.01-
56.64 1.40 >0.05 
C-reactive 
protein n=23 0-10.3 1.40 NA NA NA NA 
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 Mann-Whitney tests were used to compare data from both hospitals. Significant difference 
was found in the total protein (TP) measurements (P= 0.02). Hyperproteinemia was present in 
14% (4/28) of dogs in the Pisa group and 5% (1/21) of dogs from the Beit-Dagan group. 
  
7.4 DISCUSSION  
General Considerations 
First, it is essential to mention a potential bias risk in selection of subjects. Study exclusion 
criteria indicated elimination of cases with positive serology to infectious disease that could 
have caused the hemolytic crisis. Four suspected cases were excluded due to seropositivity to 
infectious disease despite the fact that the test is not 100% specific 
136
. Furthermore, positive 
serology in endemic areas doesn't necessarily indicate an active infection
137,138
. One case of a 
6-month-old puppy with IMHA was included in the study. The age of presentation did not fit 
the usual IMHA patient profile, and yet diagnostic procedures including serology and PCR 
were negative and could not identify a primary cause for the disease. The case was included in 
the study despite the fact that neither of the tests were  100% sensitive 
136,139
.  
Data used for this study was collected from a computerized database in Pisa and from clinical 
charts in and Beit-Dagan. Since the charts were hand-written in most cases by veterinary 
students, they were more difficult to interpret and collect into homogeneous, empirical data. 
Information was more easily retrieved from the Pisa computerized database primarily because 
it was more systematic and uniform.    
Diagnostic work-up varied between hospitals. The most significant difference was the lack of 
a manual WBC differential count in the Beit-Dagan cases. A manual differential WBC count 
is one of the vital elements of a blood smear evaluation and is preformed routinely for almost 
every blood sample in the Pisa Clinical Pathology Laboratory. The manual differential count 
was made for all cases from the Pisa group and was considered in all cases to be a more 
accurate quantification of the various leukocyte populations.  
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Some biochemistry parameters were tested for in Pisa but not in Beit-Dagan. One of them is 
the C-reactive protein (mg/dL); an important acute-phase inflammatory marker that might be 
used as for long-term monitoring of IMHA patients
37
.  A definitive diagnosis of IMHA was 
made in Pisa by means of flow-cytometry to detect antibodies anti-RBC on the surface of 
erythrocytes (n=22). At Beit-Dagan, a definitive diagnosis of IMHA was made by means of 
osmotic fragility test (n=13), which confirmed the presence of spherocytes, in-slide saline 
auto agglutination test (n=4), detection of spherocytes or micro-agglutination in blood smears. 
The cost-effective value of flow cytometry for diagnosis of IMHA is debatable. According to 
some authors 
15,34
 the presence of spherocytes or saline-persistent auto agglutination together 
with matching clinicopathological alterations is enough to make a diagnosis of IMHA. On the 
other hand, other authors 
6,8,50
 claim that either a Coombs' test or a flow-cytometry are 
necessary  in order to have a definitive diagnosis. A correct diagnosis is important in order to 
effectively treat affected dogs and avoid treating unaffected dogs with potentially harmful 
drugs
48
. In this study we have two veterinary teaching facilities that represent two different 
diagnostic approaches. Whether one approach surpasses the other in terms of treatment 
efficiency or cost-effective value is yet to be determined by further research. 
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Signalment 
Age of first clinical presentation of the disease was similar in both hospitals and no significant 
difference was noted (P>0.05). The arithmetic mean and standard deviation of age in the 
entire study population (Pisa and Beit-Dagan) was 7.00±3.36. Both groups had a similar 
(P>0.05) gender distribution. The entire study population was composed of 29% females, 
38% neutered females, 23% males and 10% castrated males. Neutered females were slightly 
overrepresented in our study. Compared with the control group, the Pisa group had a 
significantly greater proportion of neutered females (P=0.021). Study population was quite 
variable in terms of breed and 19 different breeds were represented. No significant differences 
existed between the two hospitals (P>0.05) in terms of breed representation. 54% of dogs in 
this study were mixed-breed dogs. The breeds most represented were Cocker Spaniel and 
Labrador retriever with 4 subjects of each of these breeds in the entire study population. 
However, when a comparison of proportions was made between the Pisa study group and the 
control group we found no significant difference in proportions regarding the Labrador 
Retriever breed (P>0.05). Apparently this breed is very popular in Italy and is overrepresented 
in the control group as well. Cocker-Spaniels were indeed overrepresented, even when 
compared to the control group (P=0.025). Furthermore, the Maltese breed was also 
significantly overrepresented when compared to the control group.                                                                                                             
Canine immune mediated hemolytic anemia is described in the literature as a disease of 
middle-aged dogs (6-8 years)
2,17,20
, with a higher prevalence among females
17
 and mainly 
neutered females
17,20
. The Cocker-Spaniel breed is often reported as overrepresented in IMHA 
studies
6,17,19,20,140
 and some authors claim it to have a genetic predisposition to the disease
18
. 
The Maltese breed is likewise commonly reported in studies of IMHA 
2,43,125,132,141
. Our 
findings in this study are in agreement with findings of recent studies regarding signalment 
and patient profiling.  
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Seasonality 
The question whether IMHA is a seasonal disease has been frequently debated. Some authors 
have described an increased occurrence of the disease during the warm season 
11,20,30,31
. 
Others claim that no seasonal variation exists 
6,15
. In our study, two groups from different 
climate settings were compared. No significant difference was found between the groups 
(P>0.05) and no season was particularly represented in our study (P>0.05). Increased 
exposure to infectious agents in certain seasons might be the cause of the seasonal variation 
reported by several authors
34
; some dogs with tick borne disease might be under-diagnosed 
due to the hyper-acute nature of these diseases. We suspected that in Israel, the disease would 
be more frequent during the warm season since it is considered to be endemic for some tick 
borne diseases 
142
. Possibly our sample size (n=22) is not large enough to demonstrate such 
seasonal predisposition.  
 
Clinical findings 
Symptoms reported in this study were collected from owners by veterinary students or 
clinicians. Clinical signs were collected by a clinician or a student with further confirmation 
by a clinician. The term "pigmenturia" was used as a substitute for red, dark red, orange or 
brown urine reported by owners since retrospectively it is impossible to know with certainty if 
the color alteration was due to hemoglobinuria, bilirubinuria, excessive presence of 
urobilinogen or erythrocytes in the urine.   
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Some variations were found between the clinical presentation in Pisa and the one in Beit-
Dagan. Animals presented to the Beit-Dagan hospital were more frequently tachypnoic and 
tachycardic (P=0.001 and P=0.017) than those presented to the Pisa hospital. The two clinical 
signs were also moderately correlated to each other (r = 0.55, P= 0.001). One possible 
hypothesis is that the difference is due to weather conditions which differ greatly between the 
two countries. Central Israel has a very warm climate throughout 7 months of the year that 
could explain why more dogs are presented with tachypnea and tachycardia 
143,144
. However, 
when correlations were calculated between symptoms, no correlation was detected between 
fever and rapid respiratory or heart rate. Furthermore, the arithmetic means of body 
temperature from each of the groups were very similar (38.8 Cº and 38.6 Cº in Pisa and Beit-
Dagan, respectively) and no significant difference was noted (P>0.05). Another hypothesis is 
that dogs from the Beit-Dagan group were more frequently or more severely hypoxic in 
comparison to dogs from the Pisa group and therefore had a more rapid respiratory rates
145
. 
The latter hypothesis cannot be confirmed since an arterial blood gas analysis is indicated in 
order to associate tachypnea to hypoxia and was not preformed for the majority of patients. 
Tachypnea has also been described in dogs suffering from pulmonary thromboembolism 
146
. 
The involvement of a thrombo-embolic event in tachypnoic patients with IMHA is possible, 
but a necropsy is warranted in order to confirm this hypothesis.                                                                                         
Patients from the Beit-Dagan group were also more frequently icteric than the ones from the 
Pisa group (P=0.048). Icterus or jaundice is the clinical manifestation of high serum bilirubin 
concentration and is visible in mucous membranes, skin and sclera of dogs in which levels of 
serum bilirubin exceed 1.5 mg/dL. When a hemolytic process is present, the amount of 
bilirubin in circulation exceeds the hepatocytes' capacity to perform glucuronide conjugation 
and secretion into the intestinal tract. Jaundice in IMHA dogs is often related to a more severe 
and acute intravascular hemolysis
6
 rather than the more common extra vascular hemolytic 
form of the disease. It is possible that more patients from the Beit-Dagan group had an acute 
onset of the disease. Icterus was moderately correlated to the symptom pigmenturia (r =0.51, 
P= 0.001). The latter could be explained by the renal excretion of excess bilirubin found in the 
blood prior to its clinical manifestation as jaundice. 
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 The most common symptoms in this study were lethargy (n=46), anorexia (n=34) and 
pigmenturia (n=18). Most common clinical signs were pale mucous membranes (n= 46), 
tachycardia (n=22) and tachypnea (n=20). Other frequent findings included: fever (n=19), 
cardiac murmur (n=18), icterus (n=17) and vomit (n=13).  All the above mentioned symptoms 
and signs have been commonly reported in the literature 
2,6,17,20
. Less frequent clinical 
findings in our study were lymphadenomegaly (n=8), cranial organomegaly (n=6), syncope 
(n=5) and diarrhea (n=5). These symptoms have been reported less commonly in the literature 
as well 
2,8,147
.  
Clinicopathological alterations 
Clinicopathological alterations evaluated in this study included: erythrocyte, leukocyte and 
platelet parameters and a blood smear evaluation. Additionally, a few selected biochemistry 
parameters that were previously reported by  some authors as significant for the assessment of 
disease gravity and prognosis
2,17,20,24
 were evaluated as well. 
Some differences were noted between the two hospitals regarding erythrocyte parameters. 
MCV, MCHC and RDW indexes differed significantly (P=0.004, 0.001 and 0.018, 
respectively). The MCV value is a measurement of the average volume of a patient's RBCs. 
Larger than normal RBCs are considered to be a sign of regeneration since the "younger" 
cells, known as polychromatophils, are bigger then mature erythrocytes and therefore increase 
the average size measurement. Furthermore, the common phenomenon of autoagglutination of 
RBCs in the course of a hemolytic crisis can potentially increase MCV values since the 
agglutinated erythrocytes can be counted by the automated analyzers as one large erythrocyte. 
MCV values were significantly higher in the Pisa group. A low MCHC value indicates lower 
concentration of hemoglobin inside the cells and is a typical observation in regenerative 
anemia. MCHC values were significantly lower in the Pisa group. The difference between 
hospitals could in fact indicate that some of the patients in the Beit-Dagan group were 
presented to the hospital in a pre - regenerative phase of IMHA. Interestingly, 8/21 dogs in the 
Beit-Dagan group had high MCHC values – which is considered to be a pre-analytical error 
since the erythrocyte cannot "over-saturate" with hemoglobin. This error usually indicates 
biological or mechanical hemolysis, and in the case of IMHA dogs could be an indication of 
intravascular hemolysis mediated by the immune system.  
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RDW value reported by the automated analyzers reflects the level of variability in terms of 
size among the erythrocyte population in the blood. As mentioned before, younger 
erythrocytes are bigger then mature erythrocytes. The presence of many younger erythrocytes 
can increase the RDW value and is an indication, in many cases, of erythrocyte regeneration. 
RDW values are particularly high in IMHA patients due to the significant size difference 
between spherocytes and polychromatophils.   
Regeneration of RBCs starts at three days after onset of hemolysis and peaks at seven days 
after it
148
. It is therefore possible to assume that the Beit-Dagan group is characterized by a 
more acute onset of the disease and consequently shows less signs of regeneration.  
As previously mentioned, classification of anemia was performed for all patients in which 
RBC indexes were available (51/52). Some differences were noted regarding anemia 
classification proportions between the two hospitals. The Pisa group had significantly 
(P=0.001) more patients with macrocytic-hypochromic anemia. The latter suggests a more 
frequent regenerative response in that group
5,148
. The Beit-Dagan group had significantly 
more (P=0.005) patients with macrocytic-hyperchromic anemia. The latter suggests a more 
frequent intra-vascular hemolytic process among patients from the Beit-Dagan group.  
In this study 67% of dogs suffered from severe anemia defined by a hematocrit value equal or 
lower then 20 and 33% of dogs had moderate anemia defined by a hematocrit value of less 
than 30. Classification of anemia revealed that 43% of dogs had macrocytic-hypochromic 
anemia, 27% of dogs had macrocytic-normochromic anemia, 12% of dogs had macrocytic-
hyperchromic anemia, 10% of dogs had normocytic-normochromic anemia, 4% of dogs had 
normocytic-hypochromic anemia and 4% of dogs had normocytic-hyperchromic anemia. 
RBC indexes of one dog were not available.   
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A recent review of the diagnostic approach to anemia in the dog and the cat 
148
 referred to 
hemolytic anemia as initially pre-regenerative (normocytic and normochromic). This is 
followed by a phase in which the anemia shift into the macrocytic hypochromic pattern, when 
reticulocytosis becomes relevant. In addition, a regenerative anemia may have enough 
macrocytosis to increase the MCV value, but not enough hypochromic RBCs to decrease the 
MCHC value out of the reference interval 
5
 resulting in a macrocytic-normochromic anemia. 
All phases of regenerative response to hemolytic anemia described by the literature were 
represented by our study population. Furthermore, a few patients exhibited hematologic signs 
of hemoglobinemia, which was previously described as a characteristic element of the acute 
onset of IMHA
6
. It is also possible that in Pisa, where blood sampling is preformed primarily 
by clinicians, the event of mechanical hemolysis due to difficulties in venipuncture is less 
common.    
The interpretation of erythrocyte indexes should always be made together with a blood smear 
evaluation, since they are easily altered by large numbers of abnormal RBCs. Dogs with 
IMHA often have morphologic abnormalities that can only be identified by examining the 
patient's blood smear.  
The most frequently observed erythrocyte morphologic alteration in our study was 
polychromasia followed by anisocytosis (94% and 82%, respectively). These alterations 
confirm the data received from the automated analyzers. Polychromasia and anisocytosis 
indicate that a population of young RBCs, called polychromatophils is present in the blood. 
Polychromatophils correspond frequently to reticulocytes and indicate an increased release of 
those cells from the bone marrow or from extra-medullary hemopoietic organs 
5
. Howell-Jolly 
bodies (HJB) are small round nuclear residues commonly found in RBCs in regenerative 
anemia. In this study, 49% of patients had HJB in peripheral blood. These findings are 
consistent with the definition of a highly regenerative anemia reported in other IMHA 
studies
6
.  
82 
 
Nucleated RBC's were found in 82% of blood smears. The presence of these nucleated 
erythroid cells in peripheral blood can also be referred to as normoblastemia. NRBCs are not 
normally present in the peripheral blood of healthy adult dogs except in very low percentages. 
No explanation is available on the mechanism that prevents these cells from reaching the 
peripheral circulation. The most probable hypothesis is that, possibly as a result of the 
presence of the nucleus, NRBCs are not deformable enough to pass the bone marrow sinus 
endothelium and enter into the lumen of blood vessels. Therefore, an elevated NRBC count in 
the peripheral blood may indicate disruption of the blood-bone marrow barrier or, 
alternatively , that extra-medullary haematopoiesis has been activated in response to 
anemia
149
. The trigger for this response is believed to be hypoxia
150
. Hypoxic erythropoietin-
induced compensatory erythropoiesis has been reported in human patients with 
cardiopulmonary disorders, such as pulmonary emboli and may indicate unfavorable 
prognosis
150
.  In this study, 18% of dogs had no normoblastemia, 24% had five or less 
NRBC's in blood smear, 22% had between six to ten NRBCs in blood smear and 37% had 
more than eleven NRBCs in blood smear. Normoblastemia has been frequently reported in 
dogs with IMHA
6
, yet its prognostic value for these patients is still unclear. 
Correlations between NRBCs in peripheral blood and other types of cells have been 
investigated in this study. We found a weak but significant correlation between NRBCs and 
macrothrombocytes (r=0.32, P=0.024) and band neutrophils (r=0.32, P=0.024).  This three 
cell types have been previously reported in humans and dogs in which an extra-medullary 
hematopoietic mechanism has been activated
150–152
. The combination of these three alterations 
was present in 13 dogs (25%) that took part in this study. The significance of this observation 
and its relation to extra-medullary hematopoiesis in IMHA dog cannot be confirmed without a 
fine needle aspiration (FNA) or hepatic and splenic biopsy and therefore further study of the 
subject is warranted.  
Spherocytosis and autoagglutination are the most frequently reported RBC morphologic 
alterations in patients with IMHA
6,11,20,34,92,140
. Reported percentage of spherocytosis in 
IMHA study groups vary from 70 to 80 percent in most studies
11,140
. In the present study, 80% 
of patients had spherocytosis. Autoagglutination was present in 27% of our patients. Other 
authors have reported greater percentages of autoagglutination in IMHA studies
15,140
 (60-
87%).  
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Other morphologic abnormalities found in this study include: hypochromia and poikilocytosis 
(16% of dogs), schistocytes (14% of dogs), microcytes, macrocytes, ghost-cells and target-
cells (6% of dogs) and dacriocytes (4% of dogs). Hypochromia is the visual confirmation of a 
low MCHC value indicated by the automated analyzers. It is often correlated to iron 
deficiency anemia
5
, but in our case reflects the fact that the iron reservoir is decreasing and so 
the concentration of HB in the cells is lower than normal. The cells therefore appear more 
transparent under the microscope. Poikilocytosis is a non specific term for variation in RBC 
shape and should be further classified as to the type of shape change present. Schistocytes or 
schizocytes are RBC fragmentations that may appear in the blood when RBCs are forced 
through altered vascular channels or as a result of turbulent blood flow 
5
. They have also been 
associated with disseminated intravascular coagulation (DIC) 
5
 ,thrombotic thrombocytopenic 
purpura in humans
153
 and , microangiopatic hemolytic anemia in children 
154
 as well as in 
dogs 
1
. The presence of RBC fragments in blood of IMHA dogs could be the result of DIC, 
which is a common complication of the disease. This alteration has been mentioned 
sporadically in IMHA dogs; according to Duncan and Prasse (2011) the presence of 
schistocytes suggests that excessive phagocytosis of erythrocytes is present
1
 . The clinical 
application of this observation and its correlation to DIC or pulmonary thromboembolism is 
yet to be determined. Other alterations, which had lower frequencies among this study group 
(less than 10% of dogs) are considered arbitrary and their relevance to the disease in 
inconclusive. 
As mentioned before, differential leukocyte counts were performed manually in Pisa and 
using automated analyzers in Beit-Dagan. The Beit-Dagan population had significantly more 
lymphocytes than the Pisa population (p=0.001). It is possible that the lymphocyte count was 
falsely increased by high numbers of NRBCs. Falsely increased lymphocyte counts due to 
normoblastemia is a common occurrence in the Pisa University Veterinary Clinical Pathology 
Laboratory and therefore a manual WBC count is performed for almost every blood sample 
(unless instructed otherwise).  
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The majority of our study population had leukocytosis at time of diagnosis (80%). Medians 
from both hospitals were well beyond reference intervals in both hospitals. Some dogs were 
presented with extremely increased leukocyte counts with maximum values of up to 59.9 and 
52.6 (WBCx10
3
\ ųL) in Beit-Dagan and Pisa respectively. This dramatic increase in WBC is 
defined by some authors as "Leukemoid Reaction" and has been previously described in 
IMHA patients
5,155
. The combination of the latter reaction along with the presence of NRBCs 
in peripheral blood is defined as "Leukoerythroblastic reaction" and may or may not include 
immature forms of neutrophils ("band" neutrophils)
156,157
.  Leukocytosis was most often 
neutrophilic (69%) and was accompanied by a left shift in 49% of cases. Monocytosis was 
also observed, but less frequently (31%). These findings are consistent with previously 
described leukogramms of IMHA dogs
6,15,17,34,82,140
. Activated monocytes in blood smears of 
dogs are a frequent observation at the Pisa University Veterinary Clinical Pathology 
Laboratory. In addition to their phagocytic activity, monocytes secrete a variety of cytokines 
that are involved in hematopoiesis and modulation of inflammatory response. The term 
"activated monocytes" refers to cytoplasmatic vacuolation of monocytes in fresh blood 
smears
155
.  In our study group we found microscopic evidence of monocyte activation in 43% 
of cases. Monocyte activation has been reported in people with sickle cell anemia
158
. In dogs, 
this finding may indicate a state of inflammation, but it scarcely correlates to any specific 
disease
155
. Neutrophilic toxicity and lymphocyte reactivity were reported in 25% and 20% of 
cases respectively. The presence of toxic neutrophils in non-infective disease has been 
reported previously in canine IMHA
159,160
, among other non infective pathologies. Reactive 
lymphocytes are considered to be a sign that a strong immune stimulation is present. The 
latter has been attributed mainly to viral and chronic disease, but also to auto-immune 
disease
159
. 
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Platelet counts were compared between the two hospitals, and no significant differences were 
found (P>0.05). As mentioned previously, three sub-groups based on the number of platelets 
were formed: dogs with platelet counts lower than reference range (thrombocytopenia); dogs 
with platelet counts within reference ranges; dogs with platelet counts higher than the 
reference range (thrombocytosis). Absolute numbers of platelets were also verified by the 
blood smear assessment of platelets and the presence or absence of platelet aggregates. No 
significant differences were found between the hospitals in terms of sub-group distribution 
(P>0.05). The majority of dogs (55%) had a normal platelet count, 35% were 
thrombocytopenic and 10% had thrombocytosis. Thrombocytopenia in IMHA patients is 
often mentioned in the literature, since the combined immune destruction of platelets and 
RBCs (also known as Evans Syndrome) is fairly common in dogs 
6,8,20,34,82
, as well as in 
humans
161
. Evans syndrome is correlated with a worse prognosis and increased chances of 
death 
2,17,162
 and occurs in 20-45% of IMHA cases
2,8
. Our study confirms the latter finding, 
with 35% of patients in the thrombocytopenic sub-group. Thrombocytosis can be the result of 
splenic contraction due to epinephrine release, immunosuppressive treatment and nonspecific 
bone marrow stimulation (as occurs in anemia). It was reported previously in correlation with 
extravascular hemolysis 
1
. In our study, five dogs had thrombocytosis at time of blood sample 
and it is considered an occasional finding with little or no clinical significance.  
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Platelet (PLT) morphology was evaluated in peripheral blood smears. Platelets larger than 
normal (macrothrombocytes) were seen in 45% of blood smears. Platelet activation was only 
reported once in our study (2%).  In IMHA-affected patients, platelets are a younger 
population recently mobilized from bone marrow
36
. Young platelets are larger and more 
metabolically and functionally active, and normally are sequestered in the spleen
36
. Another 
hypothesis that was previously discussed is the activation of an extra-medullary 
hematopoietic mechanism, causing release of larger than normal platelets from hemopoietic 
tissue 
150–152
 . Macrothrombocytopenia is a hereditary dysplasia in certain breeds (e.g. 
Cavalier King Charles Spaniel)
163
, but these breeds were not represented in our study. It has 
been suggested that in IMHA-affected dogs, splenic contraction, associated with anemia or 
corticosteroid administration, could reduce platelet sequestration and allow these young 
metabolically active platelets to circulate. Regardless of the cause, the presence of  
macrothrombocytes in addition to activated platelets indicates that platelets may be more 
likely to contribute to prothrombotic events in dogs with IMHA
36
. Platelet activation in our 
study refers to the morphology of the platelets seen in blood smear. Activated PLTs appear to 
have cytoplasmatic prolongations and can be the result of a laborious venipuncture. To truly 
detect platelet activation, an evaluation of cell membrane expression of P-selectin using flow 
cytometry is required
36,164
. 
A few biochemistry parameters were selected and analyzed. Selection of parameters was 
based on prognosis indicators identified by recent veterinary hematology research
77
. C-
reactive protein was selected for its possible use in monitoring response to treatment in IMHA 
patients.  
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A significant difference was noted between hospitals regarding total protein (TP) 
quantification (P=0.02), but not albumin quantification (P>0.05). An increase in plasma 
protein concentration may be present with intravascular hemolysis, resulting in artificial 
hyperchromasia that interferes with the automated reading of the analyte
1
. Surprisingly, the 
median of the Pisa group was significantly higher, although the latter group had less reported 
cases of artifactual hyperchromasia. Additionally, calculations of correlation between the two 
parameters yield no evidence of significant covariance between them (r=-0.14, P=0.341). It is 
therefore possible to assume that, since the albumin measurements did not vary significantly, 
the nature of the difference might be the plasmatic globulin concentration. Gamma or 
Immuno-globulin concentration tends to increase with infection or inflammation that causes a 
strong antigenic stimulation
155,165
. Furthermore, Acute phase proteins such as serum amyloid 
A, C- reactive protein and fibrinogen increase within 24-48 hours following tissue damage or 
inflammation
159,166
. These plasmatic elements may be the origin of a relative increased in TP 
among the Pisa group. Nonetheless, in order to properly study protein alterations a serum 
protein electrophoresis (SPE) is required. SPE was not performed in the majority of IMHA 
cases presented to the veterinary hospitals and was not evaluated in this study. 
Hyperproteinemia was present in 14% of dogs in the Pisa group and 5% of dogs from the 
Beit-Dagan group. This alteration has been formerly discussed by some authors
76,77,166
, and 
can be used along with other parameters to predict the outcome of  the disease 
76,77
.  
Increased bilirubin was frequently reported in both hospitals. Medians were increased three 
and seven times higher in comparison to the upper reference value in Pisa and Beit-Dagan, 
respectively. Although no significant differences were noted between hospitals (P>0.05), the 
median in Beit-Dagan was distinctively higher and may justify the increased number of 
patients presented with icterus. Pre-hepatic, hemolysis induced hyperbilirubinemia is very 
commonly reported in IMHA patients
2,11,20,77
 and as discussed formerly can be used along 
with other parameters to predict the outcome of  the disease
77,167
. Measurement of C - reactive 
protein (CRP) was only available for the Pisa group. A recent study investigated serum 
concentrations of CRP in thirty dogs with IMHA. The authors found that all dogs with IMHA 
had CRP values higher than the reference interval at time of presentation 
37
. In the present 
study, 78% (18/23) of dogs that were tested for CRP serum concentrations had values higher 
than reference range.              
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7.5 CONCLUSIONS 
This retrospective study of 52 dogs with primary IMHA confirms the findings previously 
described by the literature regarding clinical and clinicopathological alterations of this 
complex disease.  
Reviewing the results, it is possible to draw some conclusions about the nature of the two 
groups collected. The Beit-Dagan group was characterized by a more severe and acute onset 
of IMHA, with more evidence of intravascular hemolysis and a slightly lower Hct median. 
Some dogs in this group were presented in a pre-regenerative phase of IMHA, a fact that may 
suggest a more acute presentation of the disease. The Pisa group was characterized by less 
acute onsets and more cases were referred to the hospital for the purpose of specialist 
consulting. We had the clinical impression that mortality rates in Pisa were lower, but the 
latter cannot be confirmed since many cases were lost in follow-up in both hospitals.  
In this study, the vast variety of morphological anomalies of cellular components in the blood 
of IMHA patients was thoroughly investigated. A few questions arise from our work that 
could form the basis for future research. The combination of NRBCs, band neutrophils and 
macrothrombocytes and its relation to extra-medullary erythropoiesis should be investigated 
using hepatosplenic cytology. The presence of schistocytes in IMHA patients' blood smears 
and the possibility of using them as biomarkers for DIC or pulmonary thromboembolism 
should be investigated using advanced diagnostic imaging techniques or post-mortem 
autopsies. The involvement of macrothrombocytes in the mechanisms that cause hyper - 
coagulative state of IMHA patients should be evaluated using thromboelastography.  
In conclusion, the blood smear evaluation is an important instrument in the hands of the 
internal clinician and may, in many cases help guide our clinical and therapeutical decision 
making. In the case of immune mediated hemolytic anemia the blood smear evaluation 
reveals the battle-field in which the pathologic process is taking place and may contribute 
important information regarding coagulopathies and host response to the immune disorder.   
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APPENDIX. 1: Reference intervals. 
 
Parameter Pisa  Beit-Dagan 
RBC 106 /µL 5.65 - 8.87 5.7 - 8.8 
Htc% 37.3 - 61.7 37.1 - 57.0 
HGB g/dL 13.3 - 20.5 12.9 - 18.4 
MCV fL 61.6 - 73.5  58.8 - 71.2  
MCH pG 21.2 - 25.9 20.5 - 24.2 
MCHC g/dL 32.0 - 39.7 31.0 - 35.7 
RDW % 13.6 - 21.7 11.9 - 14.5 
PLT K/µL 148 - 484 143 - 400 
WBC × 103/ µL 5.06 - 16.76 5.02 - 13.9 
Neut × 103/ µL 2.96 - 11.64 3.9 - 8.0 
Lymph× 103/ µL 0.7 - 5.1 1.3 - 4.1 
Mono× 103/ µL 0.2 - 1.7 3.3 - 10.3  
Eosi× 103/ µL 0.1 - 1.35 0 - 0.6 
TPP g/dL 5.8 - 7.8 5.4 - 7.6 
Alb g/dL 2.6 - 4.1 3.0 - 4.4 
Tbil mg/dL 0.07 - 0.30 0.0 - 0.2 
CRP mg/dL 0 - 0.3   -  
 
 
 
 
 
 
     
 
 
 
